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ABSTRACT
Drug addiction is a chronic disorder characterized by obsessive and uncontrollable drugseeking behaviors. It is a major public health problem globally as well as in the United States.
Apart from causing severe medical complications it also leads to several socioeconomic
problems like healthcare expenditures, lost earnings and increase in drug-related crime. The
discovery and development of potential pharmacotherapies to treat cocaine dependence has been
a high priority for more than two decades but still there is US-FDA approved medication. This
illustrates the need for the development of effective medication to treat cocaine and
methamphetamine abuse. Sigma receptors have recently been identiﬁed as potential targets for
the development of novel therapeutics. The affinity of cocaine and methamphetamine to sigma
receptors represents that targeting these receptors using selective antagonists will be an effective
strategy in the development of novel medications. This dissertation is primarily focused on the
role of metabolism and pharmacokinetics in the lead optimization of novel sigma receptor
antagonists to treat abuse of cocaine and methamphetamine.
Taking this in to consideration, we first determined in vivo and in vitro properties of
CM156,

[3-(4-(4-cyclohexylpiperazin-1-yl)butyl)benzo[d]thiazole-2(3h)-thione]

a

highly

selective sigma receptor antagonist using a validated UPLC/MS method. However due to its poor
in vivo and in vitro performance further research was halted. Several analogs were then
synthesized by blocking the metabolic soft spots of CM156. We performed a preliminary
screening of a series of the high affinity sigma receptor antagonists using in vitro metabolism
studies and selected AZ66, 3-(4-(4-cyclohexylpiperazine-1-yl)pentyl)-6-fluorobenzo[d]thiazole
ii

2(3h)-one, as a lead compound. AZ66 is an optimized sigma receptor ligand with high metabolic
stability that has been shown to mitigate behavioral eﬀects of methamphetamine, suggesting that
it can become a potential candidate to treat methamphetamine abuse. We determined its
physicochemical properties such as solubility, pKa, Log PO/W and Log DPBS, (pH 7.4). We have also
assessed its in vitro metabolic stability and in vivo pharmacokinetic parameters and absolute
bioavailability in rats using a validated UPLC-MS/MS method. We conducted repeated dose
pharmacokinetic studies and estimated the plasma steady state concentrations. More importantly
we estimated its extent of central nervous system penetration using brain to plasma ratio studies
in rats. The results of these in vitro and in vivo studies will lead to development of successful
pharmacotherapies for cocaine and methamphetamine abuse.
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LIST OF ABBREVIATIONS
Abbreviation

Meaning

ADME

Absorption, distribution, metabolism and elimination

AUC

Area under the curve

B/P

Brain to plasma ratio

BBB

Blood-brain barrier

cAMP

Cyclic Adenosine Mono Phosphate

CID
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CL

Clearance

CLint

Intrinsic clearance
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Maximum plasma concentration

CNS

Central nervous system
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Oral bioavailability
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Flavin monooxygenase
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Gastro intestinal tract
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Good manufacturing practice

GLU

Glutamate
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HIV

Human immunodeficiency virus
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Human liver microsomes
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High performance liquid chromatography

IACUC

Institutional Animal Care and Use Committee

IgG

Immunoglobulin G
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Internal standard

IV

Intravenous
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LC
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LC-MS/MS

Liquid chromatography/mass spectrometer

LLOQ

Lower limit of quantification
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Lower limit of detection

MA

Methamphetamine

MRM

Multiple reaction monitoring

MRT

Mean residence time

NADP

Nicotinamide adenine dinucleotide phosphate

NCE

New chemical entity

NE

Norepinephrine

NMDA
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NMR

Nuclear magnetic resonance

PBS

Phosphate buffered saline

PCP

Phencyclidine

PET

Positron Emission Tomography

PK

Pharmacokinetics

pKa

Acid dissociation constant
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QC

Quality control

RDS

Reward-deficiency syndrome

RE

Relative error

RSD

Relative standard deviation

S/N

Signal to noise ratio

SARs

Structure-activity relationships

SIR

Selected ion recording

SIM

Selected ion monitoring

t1/2

Half-life

Tmax

Time of maximum concentration

UDPGA

Uridine 5'-diphospho-glucuronic acid

UNODC

United Nations Office on Drugs and Crime

UPLC/MS/MS

Ultra performance liquid chromatography/mass spectrometer

US-FDA

United States Food and Drug Administration

UV

Ultra violet

Vd

Volume of distribution

5-HT

Serotonin
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CHAPTER - 1
INTRODUCTION
1.1. Cocaine abuse and addiction
Drug addiction is a chronically relapsing disorder characterized by (1) compulsion to
seek and use the drug, (2) loss of control for intake of the drug, and (3) the emergence of a
negative emotional state (eg, dysphoria, anxiety, and irritability) reflecting a withdrawal
syndrome when access to the drug is prevented. Drug addiction is conceptualized as a chronic
disorder that involves both impulsivity and compulsivity that yield a composite addiction cycle
of three stages: ‘intoxication', ‘withdrawal/negative affect', and ‘preoccupation/anticipation'
(craving) [1, 2].
Impulse control disorders are characterized by an increasing sense of tension compelling
an impulsive act and pleasure, or relief at the time of committing the act. Impulse control
disorders are largely associated with positive reinforcement mechanisms. In contrast, compulsive
disorders are characterized by anxiety and stress before a compulsive repetitive behavior and
relief from the stress by performing the compulsive behavior. Compulsive disorders are greatly
associate with negative reinforcement mechanisms [3]. Cocaine addiction is characterized by
impulsivity, impaired social relationships, and abnormal mesocorticolimbic reward processing
[4]. Mesocorticolimbic circuits, involving the dopaminergically innervated ventral and dorsal
striatum as well as orbitofrontal and anterior cingulate cortices, are crucially involved in reward
processing, and dysregulation in these circuits is implicated in both impulsivity and cocaine
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dependence [5]. A possible explanation for diminished mesocorticolimbic activation is the
reward-deficiency syndrome (RDS) hypothesis [6], which assumes that drugs of abuse, due to
their potent dopaminergic effects, normalize ventral striatal dopamine levels, leading RDS
individuals to consume cocaine or other abused drugs [1, 7].
Despite several efforts, the treatment of cocaine abuse has proven to be insubstantial and
there is currently no US FDA-approved drug to treat cocaine addiction. The primary effect of
cocaine on the central nervous system (CNS) is reuptake blockade of monoamines. Cocaine
binds with dopamine transporters (DAT) in the same binding pocket as dopamine (DA) and
prevents reuptake of DA. As a result of this, the short-term effects of cocaine, like euphoria,
begin [8]. The long-term effect of cocaine addiction involves cocaine-induced changes in the
brain’s communication system, including the rapid upregulation of DAT expression on the cell
surface. A single use of cocaine will increase the surface DAT expression for at least a month,
due to the increase of the surface DAT expression with chronic use, there are less DA molecules
available in the synapse for signaling, which might contribute to the drug seeking or carving [9].
In general, two aspects have to be taken into consideration for the treatment of drug
addiction: antagonizing the stimulant and toxic effects of the abused drug and restoring the
functions of brain back to normal. Without antagonizing the effects of cocaine, it may prove
difficult to bring the function of the brain to normal. The main reason behind this is when
cocaine is taken it will increase expression of the surface DAT for at least a month and the
function of the brain cannot be normal [10]. Henceforth, it is necessary to antagonize the
stimulant effects of cocaine for the treatment of cocaine-addiction.
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Cocaine addiction and overdose are major medical and public health problems that
challenge the treatment. The traditional approaches to treat addiction include targeting a specific
subtype of transporters/receptors that affect various neurotransmitter systems, such as
dopaminergic, serotonergic, noradrenergic, cholinergic, glutamatergic, GABAergic and
opioidergic pathways, and modulate neurological processes [10].
Cocaine is available primarily in two forms: cocaine hydrochloride salt and the free base.
The salt form is a white powder and is water soluble, so it can be taken intravenously or
intranasally. The free base, also called as “crack” is white to light brown in color and is insoluble
in water. “Crack” is derived from the crackling sound produced when it is heated. Crack cocaine
is often smoked or injected [11]. Cocaine available as non pharmaceutical or illicit drug on the
streets contains many adulterants. A recent finding has shown that 70 % of the cocaine that is
seized in the USA contains levamasole, an anti-helminthic drug. Cocaine adulterated with
levamasole has been responsible for many deaths and emergency cases. However, the particular
reason behind the adulteration with this specific drug was not identified [12].
1.2. Pharmacokinetics of cocaine
After entering in to the body and systemic circulation, cocaine is metabolized by the liver
and plasma cholinesterases into pharmacologically inactive metabolites such as benzoylecgonine
and ecgonine methyl ester. Urinary metabolites constitute 90% of the actual cocaine dose and a
very small percentage is excreted as unchanged compound in the feces [12]. Cocaine is
consumed usually via oral, intranasal, intravenous and pulmonary routes. The rate of entry of
cocaine in to the systemic circulation depends on the route of administration, the quicker being
the smoked or intravenous (i.v.) administration. After oral or intranasal administration plasma
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concentration increases slowly. These differences in the entry rate explain the greater reinforcing
effects produced by the i.v or smoked compared to oral or intranasal cocaine. Rapid increases in
plasma concentrations of cocaine are directly correlated to its physiological and subjective
effects [11].
1.3. Pharmacology of cocaine
The mesocorticolimbic reward system consists of dopaminergic cells in the ventral
tegmental area (VTA) and their projections to the nucleus accumbens (NAc) and prefrontal
cortex (PFC), as well as glutamate (GLU) projections from the PFC to both the VTA and NAc.
Other important brain structures associated drug dependence are amygdala, hippocampus and
hypothalamus [13]. Cocaine rapidly increases dopamine levels in the PFC and NAc. Even
though various neurotransmitter systems are involved, many studies suggest that activation of the
mesocorticolimbic system is primarily responsible for the reinforcing effects produced by
cocaine in humans [14].
Despite the fact that cocaine exhibits numerous physiological and neurological effects on
this system, the primary mechanism underlying its reinforcing effects is inhibition of reuptake of
DA [15]. Figure 1.0 gives pictorial representation of mechanism of cocaine. Many studies have
shown that cocaine’s reinforcing properties are related to its ability to increase synaptic DA by
binding to DAT. In fact, rendering DAT insensitive to cocaine by molecular engineering had
proven to abolish its potent reinforcing effects [16]. Several studies have associated DA
neurotransmission explicitly with cocaine induced euphoria.
Dopamine receptor antagonists attenuate the positive subjective effects of cocaine in
humans partially by interrupting the DA neurotransmission [17]. However, complete blockade
4

was not achieved by selective pacification of DA suggesting the involvement of other transmitter
systems. In addition many, compounds that are promising for dependence alter norepinephrine
(NE) neurotransmission through a number of mechanisms [18, 19].

Figure 1.1: Classical mechanism of action of cocaine
1.4. Cocaine pharmacotherapies
1.4.1. Dopaminergic medications
Currently, dopamine receptors are classified in to two types of receptor families:
dopamine D1-like family and dopamine D2-like family. D1 and D5 receptors that initiate cyclic
adenosine mono- phosphate (cAMP) formation fall under D1-like family. The D2-like family
that includes D2, D3 and D4 receptors inhibits the cAMP formation [20]. The acute and chronic
effects of cocaine are proposed to be mediated by both D1 and D2-like receptors. Some of the
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dopaminergic compounds that were tested for treating cocaine addiction are modafinil, mazindol,
disulfiram, nepicastat, methylphenidate, selegelline, amantadine and bromocriptine. The
following paragraphs provide a brief out-line of the few of these dopaminergic agents that are in
clinical trials.
Methylphenidate is used for the treatment of narcolepsy and attention-deficit
hyperactivity disorder (ADHD). Methylphenidate was proposed as an ‘agonist treatment’ for use
in cocaine addiction because it stimulates the release of dopamine and inhibits reuptake of
dopamine, norepinephrine and serotonin [21].
Disulfiram is an aldehyde dehydrogenase inhibitor as well as a dopamine-betahydroxylase (DBH) inhibitor. It is currently approved for treatment of alcohol dependence.
Dopamine-beta-hydroxylase converts dopamine to norepinephrine leading to increased DA
levels in the brain and inhibition of DBH leads to a decreased neuronal and synaptic
norepinephrine levels compared to dopamine [22, 23]. A recent study has shown that the coadministration of disulfiram with cocaine increased the plasma cocaine concentrations 3 to 6
fold, which perhaps contributed to the decreased craving and increased dysphoria observed
during the study. In a double-blind randomized clinical study of disulfiram for the treatment of
cocaine dependence in methadone-stabilized individuals, it was observed that there was a
considerable decrease in cocaine-positive urines in the group receiving 250 mg/day compared to
lower doses like 62.5 mg and 125 mg, of the medication or placebo [24]. These findings suggest
that disulfiram may be a potential medication for treating cocaine abuse. Nonetheless, additional
studies with disulfiram are needed to determine the optimal dose and duration of treatment.
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Nepicastat, like disulfiram, is a novel selective DBH-inhibitor and is currently under
investigation treating cocaine dependence. In preclinical studies, nepicastat has shown to
decrease brain noradrinaline levels but increase dopamine synaptic levels. These results suggest
that nepicastat, would be a potential candidate to treat cocaine dependence [25].
Modafinil promotes wakefulness and is used in the treatment of hypersomnia and
narcolepsy. Even though little is known about its mechanism of action, there is evidence that
shows that modafinil acts as a central alpha-1 adrenergic agonist, and increases both dopamine
and glutamate release in specific areas of the brain [26]. As chronic cocaine use is associated
with depletion of extra-cellular glutamate levels and glutamatergic synaptic strength in the
nucleus accumbens, modafinil might serve as a promising candidate for treatment of cocaine
dependence. Modafinil pretreatment at two oral dosages (200 mg and 400 mg) demonstrated
significant attenuation of euphoria caused by the cocaine intravenous administration [27].
Modafinil reduces, craving for cocaine, cocaine use among sub-populations of cocaine users and
it has partial reinforcing effects and thus continues to represent as a promising candidate for the
treatment of cocaine dependence.
Since cocaine elicits its effects by increasing the synaptic DA levels, for several years
research has been focused on discovering a therapeutic candidate that blocks DA receptors.
Unfortunately, this strategy has not been fruitful. As a result the current researchers are focusing
more on other neurotransmitter systems such as norepinephrine (NE).
1.4.2. Cocaine effects on norepinephrine neurotransmission
Not only does cocaine bind to DAT, it also blocks the reuptake of 5-hydroxytryptamine
(5-HT) and NE and elevates synaptic levels of these neurotransmitters. Even though NE plays a
7

greater role in regulating increasing in DA, several studies indicate that 5-HT also contributes to
some of the behavioral effects generated by cocaine [28]. It was suggested that modifying the NE
production through genetic alterations or by administering drugs that facilitate NE release
cocaine’s effects could be altered significantly [18, 29]. Nevertheless, the precise role of NE in
mediating psychostimulant behavioral effects in humans still remains uncertain. Cocaine binds to
norepinephrine transporters the dopamine transporter, indicating that the modulation of
mesocorticolimbic dopaminergic transmission can be achieved through alternative pathways
[30].
Bupropion is a norepinephrine and dopamine re-uptake inhibitor currently FDA approved
as an antidepressant and also to help smoking cessation. It was shown that in a 12-week placebocontrolled trial on cocaine-abusers bupropion reduce cocaine use in depressed patients. In a
recent study, the combination of bupropion administered at a dose of 300 mg/day with
contingency management was found to significantly decrease the proportion of cocaine-positive
urine samples [31].
Venlafaxine is a mixed norepinephrine and serotonin inhibitor. When administered at a
dose of 225 mg/day was shown to produce a small but obvious reduction in euphoria induced by
cocaine. A double-blind, placebo-controlled design was conducted with nefazodone, an
antidepressant, which has serotonin and norepinephrine re-uptake inhibition as well as 5-HT2 a
receptor antagonist effects. It was observed that urine benzoylecgonine, the major metabolite of
cocaine, declined quickly in the nefazodone group compared to the placebo group [32].
Atomoxetine is a long-acting selective norepinephrine re-uptake inhibitor that is
approved for the therapy of ADHD in children and adults. This is currently in trials as a potential
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therapeutic compound for treatment of cocaine abuse and addiction in patients suffering with
ADHD [30].
1.4.3. Adrenoceptor antagonists
Cocaine also activates the adrenergic system, which includes the central noradrenergic
system and its peripheral counterpart the sympathoadrenal system. It has been shown that the
adrenergic system plays a role in mediating the physiological response to cocaine including
increases in heart rate, blood pressure and arousal. Adrenoceptor antagonists have inhibited some
of the behavioural and toxic effects of cocaine in rats, suggesting its role in mediating cocaine
effects. Propranolol, carvedilol and labetalol are few of the adrenoreceptor antagonists tested for
cocaine treatment [33].
A recent study has shown that an acute treatment with 50 mg of carvedilol attenuated
cocaine induced changes in heart rate along with systolic and diastolic blood pressure. However,
self-administration of cocaine was found to be decreased when subjects received carvedilol at a
dose of 25 mg rather than 50 mg. Based on these results, it was proposed that β-adrenoceptor
antagonists may attenuate the reinforcing effects of cocaine. However, further studies are needed
to confirm the use of adrenoceptor antagonists for the treatment of cocaine addiction [20].
Cocaine users usually exhibit reduced cerebral blood flow and deficits in the cortical
perfusion with areas of both hypo and hyper perfusion. This reduced cerebral blood flow is likely
to be associated with some of the neuropsychological impairments in verbal learning, memory
and attention commonly observed in cocaine addiction [34]. In a recent study, cocaine users
(n=9) with cerebral blood flow deficits on single proton emission computerized tomography
(SPECT) scans were compared with cocaine users (n=6) having no deficits after 2-day treatment
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with isradipine administered at a dose of 15 mg/day. Isradipine, is a calcium channel blocker
used in treatment of hypertension. It was found that isradipine improved cerebral blood flow in
areas of hypoperfusion. It also attenuated various cocaine-induced responses like ischemic
changes in the brain and altered systolic blood pressure [35]. These early studies suggest that
vasodilators may be helpful in reversing cerebral hypoperfusion observed in cocaine users.
1.4.4. Glutamate medications
Glutamate neurotransmission plays a significant role in reward and reinforcement caused
by drugs of abuse. Glutamate receptors may be one of the potential therapeutic targets for the
treatment of cocaine dependence [36, 37]. Glutamate, the most widely spread excitatory
neurotransmitter in the brain, is essential for a numerous processes including long term
depression, extinction, and reward-related learning [38, 39]. Various preclinical studies have
shown that projections of glutamate neurotransmitter from the PFC to the NAc are critical for
stress- and cocaine-primed restoration of turned off cocaine self-administration in animals.
Cocaine self-administration was reinstated when glutamate ionotropic receptor agonist AMPA
(alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid) was infused into the NAc, while
the effect was successfully attenuated by blocking the translation and expression of the AMPA
receptor subunit using antisense oligonucleotides, glutarate receptor 1(GLuR1) [40].
Glutamate levels in the brain positively correlated with chronic use of cocaine suggesting
that the continuous exposure to cocaine brought changes in glutamate. These studies suggest
glutamate receptors may become one of the pharmacotherapeutic targets for cocaine dependence.
Few ionotropic ligands have been introduced for clinical use in neurodegenerative disorders and
are now being tested for pharmacotherapy of cocaine addiction [41].
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Various N-methyl-D-aspartic acid (NMDA) receptor antagonists including competitive
(memantine), non-competitive (modafinil, lamotrigine, and ibogaine) antagonists were shown to
counteract relapse and drug-seeking behavior in animals. These drugs inhibit dopamine receptor
sensitization, which usually seen in cocaine addiction [42]. Memantine, was shown to inhibit
cocaine self-administration in rats and in a dose-dependent fashion it also suppresses cocaineconditioned motor response [43]. In humans memantine has been shown to augment the feeling
of pleasure induced by cocaine [44].
In poly drug users, ibogaine was reported to reduce craving for cocaine and heroin. It also
enhances glutamate effects by blocking its uptake by glial cells, and by increasing the release
from cortical synaptsomes. In series of trials Mash et al. found that ibogaine significantly
decreased craving for cocaine and heroin during inpatient detoxification [45]. However, it is a
potentially addictive compound, which is reported to induce neurotoxic effects and its use for
treatment of drug addiction is always questionable.
Modafinil, an alpha-1adrenergic agonist and a noradrenaline reuptake inhibitor, is a safer
agent acting on glutametergic pathways, which is currently approved for narcolepsy. It is also a
glutamate agonist. Modafinil was well tolerated, thus leading to valid treatment retention. It was
proposed that modafinil promotes cocaine abstinence owing to its ability to restore normal
glutamate baseline levels in the nucleus accumbens by reversing cocaine induced dopamine
dysregulation [46].
Lamotrigine, an approved anticonvulsant which is used in the long-term treatment of
bipolar disorder is one more drug acting on glutametergic pathways. Lamotrigine has a broad
range of effects on brain cells. It decreases sustained, repetitive, high-frequency firing of voltage-
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dependent sodium channels that may result in a preferential decreased release of presynaptic
glutamate. A study showed that lamotrigine administered at a dose of 300 mg/day was effective
in decreasing craving for cocaine; however it was not effective in patients diagnosed with bipolar
disorder [47].
1.4.5. GABA system
Gamma-amino butyric acid (GABA) system is presently receiving increased attention as
a potential target to treat cocaine dependence. GABA is a widely distributed neurotransmitter
that primarily mediates inhibition in the brain [48]. GABA receptors are classified in to 2 types
GABAA and GABAB. GABAA receptors belong to the superfamily of ligand-gate ion channels.
Their activation decreases neuronal excitability by increasing chloride influx while GABAB
receptors mediate the slow inhibitory response to GABA [49]. GABAB receptors are coupled to
G-proteins and are found both pre- and postsynaptically. GABAB receptors antagonists block
calcium channels and act as autoreceptors, diminishing neurotransmitter release presynaptically.
Postsynaptically they open the potassium channels, leading to reduced neuronal excitability and
hyperpolarisation [50].
Evidences suggest that GABA modifies the dopaminergic system and cocaine effects.
These include; (1) striatum and nucleus accumbens which contain dopaminergic neurons also
contain GABAergic synapses, this suggests the anatomical relationship between GABA and
dopaminergic systems. (2) Chronic cocaine intake changes the functional coupling of GABA
receptors and also the subunit composition of GABAA receptors. (3)Treatment with vigabatrin,
(gamma-vinyl-GABA) that acts by inhibiting the breakdown of GABA attenuates cocaineinduced locomotor hyperactivity and release of DA in the nucleus accumbens in rats [51, 52].
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GABA medications that are being tested for pharmacotherapy of cocaine are topiramate,
valproic acid, baclofen, gabapentin, tiagabine and progesterone. Baclofen, a selective GABAB
receptor agonist, is used widely as a treatment of spasticity in spinal cord injuries or multiple
sclerosis. It has shown efficacy in preclinical trials for treatment of cocaine dependence.
Baclofen was shown to attenuate cocaine seeking behavior and reduced self-administration of
cocaine dose-dependently in rats. It also inhibited cocaine-induced release of dopamine in the
nucleus accumbens [53]. A clinical trial showed significant reductions in cocaine use in baclofen
treated subjects than those receiving the placebo. However, baclofen did not demonstrate a
statistically significant impact on cocaine craving but it can be used in patients who need
treatment for relapse prevention [54]. Baclofen appears to be a well tolerated drug with no side
effects but its short half-life (3–4 h) is the major concern as it leads to poor patient compliance.
Topiramate, is an approved antiepileptic drug, that controls dopamine release in the
nucleus accumbens by enhancing GABAergic inhibitory activity and by blocking the excitatory
effects of glutamatergic neurons [55]. Topiramate antagonizes glutamatergic afferents to the
meso-corticolimbic dopaminergic system. In a randomized, double-blind, placebo-controlled
study it was shown that topiramate could not reduce cocaine use significantly. But after week
eight of the study, it was found from the urine benzoylecgonine test that subjects treated with
topiramate were more likely to be abstinent from cocaine compared to the subjects given a
placebo [55]. Clinical trials with tiagabine, gabapentin and baclofen in cocaine users resulted in
promising findings suggesting that the GABA system may be a potential target for cocaine
pharmacotherapy.
1.4.6. Serotonergic system
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In addition to its interaction with the dopamine and norepinephrine transporters, cocaine
also binds to serotonin transporters (SERT), resulting in the inhibition of presynaptic uptake of
this monoamine. Cocaine has high affinity for the serotonin transporters (Ki =217 nM). The
higher dopamine transmission in the nucleus accumbens during acute cocaine intoxication is
accompanied by enhanced release of serotonin [56]. Also cocaine withdrawal is characterized by
reduced levels of seratonin in the nucleus accumbens and depletion of serotonin levels in the
brain.
It was reported that the management of the serotonergic system mitigates drug craving in
humans. Although the results were inconclusive, these studies suggested that serotonergic
receptors might become potential targets for the drug development to treat cocaine addiction
[57]. Many studies have shown 5-HT3 receptor activation mediates the reinforcing effects of
cocaine partially in posterior ventral tegmental area [58]. Initial preclinical studies in rats
demonstrated that serotonin-enhancing compounds were associated with reduced selfadministration of cocaine, but in human clinical trials of selective serotonin reuptake inhibitors
varied results were observed [59].
Ibogaine, an indole alkaloid was found to be promising for the treatment of dependence
caused due to multiple drugs like cocaine, alcohol, opium, and methamphetamine. Ibogaine has
an affinity for a number of receptor sites including sigma-1 and sigma-2, opioid (kappa, mu, and
delta), nicotinic, DAT, NMDA and SERT. Ibogaine and its metabolite noribogaine have been
found to increase 5HT in the brain extracellularly and both of them have shown to reduce
cocaine self-administration appreciably [60, 61].
1.4.7. Immunotherapies
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One of the approaches for the persistent reduction of the reinforcement effects of cocaine
is to prevent its access to the brain. This blockade precludes the occupation of the receptors in
the brain which is required to elicit pleasurable and reinforcing effects of abused drugs like
cocaine and methamphetamine. To understand the underlying mechanism, the antibody affinity
as well as the total amount of the antibody in circulation must be known [62]. The use of
vaccinations for treating cocaine addiction effectively requires a complete understanding of the
mechanisms of antibody blockade and the immunological factors that control the progress of
antibody responses.
Currently, the vaccines for treating cocaine and methamphetamine are in the clinical and
preclinical development stages, respectively. The cocaine vaccine, TA-CD is a conjugate of
cocaine hapten and inactivated cholera toxin B that stimulates antibody production. The
generated antibodies are specific to cocaine [63]. When cocaine reaches the blood, it binds to
TA-CD resulting in the creation of larger immune complexes that are unable to cross the bloodbrain-barrier. These molecules are then metabolized by cholinesterases into inactive metabolites
which are excreted in urine [64]. In a phase I clinical study (n=34), it was observed that human
subjects receiving TA-CD generated immunologic response which resulted in the creation of
cocaine-specific antibodies [65]. Higher doses resulted in higher mean antibody levels. In all the
studies, the vaccine exhibited a favorable safety profile. Currently, TA-CD is under large-scale,
multisite, phase IIb clinical testing [22].
However, a number of investigations on noradrenergic, adrenergic, serotonergic and
muscarinic mechanisms propose that due to limited efficacy and unfavorable side effect they
may be less favorable targets for development of therapeutic candidates to treat cocaine abuse.
Therefore, current studies more focused on the sigma receptors.
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1.5. Methamphetamine abuse and pharmacotherapies
Methamphetamine (MA) abuse is a serious social and medical problem globally and in
the United States as well [66]. Methamphetamine is developed from the parent drug
amphetamine and was used originally in nasal decongestants. Commonly it is known as “meth”,
“speed”, and “chalk”. The smoked form is referred as “crystal”, “crank”, and “glass”. The major
routes of administration of MA are oral, intranasal, inhalation and injection. Methamphetamine
has multiple effects on the central nervous system. Like cocaine it produces euphoria and
increased activity. However, the effects of MA last longer than (6- 8 h) cocaine and
amphetamine [67]. It is a highly potent releaser of monoamines by increasing cytoplasmic
concentrations of dopamine and serotonin and also norepinephrine, adrenaline and histamine.
Preclinical and clinical studies have demonstrated that its use can produce irreversible neuronal
damage and serious neuropsychiatric consequences. The acute use in higher quantities may cause
a serious psychotic syndrome known as the MA psychosis. Discontinuation after the chronic use
frequently results in a withdrawal syndrome including increased appetite, sleep disturbances,
dysphoric mood and fatigue [67, 68]. Despite the seriousness, currently there are no FDAapproved medications for MA addiction. Some of the promising medications for treating MA
addiction include rivastigmine, modafinil, bupropion and lobeline [69].
Bupropion, a DA reuptake inhibitor is currently approved for the treatment of depression
and nicotine dependence. Extended use of MA reduces dopamine concentrations in the synapse.
Bupropion reinstates the dopamine homeostasis by increasing the dopamine concentration in the
synaptic cleft. In preclinical studies bupropion has reduced the neurotoxic effects produced by a
single large dose of MA. In a double-blind, placebo-controlled trial, it was found that bupropion
was effective in increasing the time of abstinence in male patients with MA dependence [70].
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Modafinil is an antidepressant that may beneficial in treating the dysphoria associated
with MA withdrawal. It is likely to decrease MA craving and may also improve the cognitive
functions in MA dependent patients, Therefore it may be used to improve the response to
behavioral therapies. Currently, modafinil is under clinical trials for the treatment of MA
dependence [71].
Acetylcholine is implicated in the reinforcing and locomotor effects caused by the use of
MA. Therefore, acetylcholinesterase (AChE) inhibitors may play a vital role to bring down
methamphetamine seeking behavior. Donepezil, a reversible acetylcholinesterase inhibitor, is
currently used for the treatment of dementia attenuated the reinstatement of methamphetamineseeking behavior stimulated after self-administration in rats [72].
Rivastigmine, another AChE inhibitor, has an afﬁnity for dopaminergic, adrenergic,
muscarinic or opioid receptors. In a two week human laboratory study 3 mg of rivastigmine
substantially reduced methamphetamine-induced rise in diastolic blood pressure and also craving
and anxiety [73]. However, there are no recent reports of clinical trials of rivastigmine to treat
methamphetamine dependence.
Lobeline is

currently

in

clinical

trials

for methamphetamine abuse

treatment. Lobeline interacts with nicotinic receptor subtypes, DAT, and vesicular monoamine
transporters [74]. It was shown that pretreatment with lobeline (0.3–3.0 mg/kg) in rats has
decreased the response for d-methamphetamine reinforcement. Furthermore, increased dose of dmethamphetamine did not surmount the lobeline-induced decrease in responding for MA. These
results suggest that lobeline may be an effective, novel pharmacotherapy for methamphetamine
abuse [75].
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Principles of drug discovery
The hunt for new drugs can be divided into two stages: discovery and development. Drug
discovery includes generating a hypothesis of the target receptor for a particular disorder and
screening the in vitro and/or in vivo biological activities of the new drug candidates. Drug
development involves the assessment of efficacy and toxicity of the new drug candidates. To aid
in a discovery program, accurate data on pharmacokinetics and metabolism must be available as
early as possible since it ultimately contributes to the eventual success or failure of the
compound. The advent of early absorption, distribution, metabolism and excretion (ADME)
screening has dramatically decreased the proportion of compounds failing in clinical trials due to
these reasons. The main aim of preclinical ADME is to eliminate weak drug candidates in the
early stages of drug development which allow resources to be focused on fewer and more-likelyto-succeed drug candidates. Withdrawing a drug from the market is a huge loss economically,
therefore an early recognition of potential problems results in a substantial savings [74, 75].
Early ADME not only provides the necessary data for selecting preclinical candidates, it can also
accelerate the timeline for investigational new drug applications and subsequently new drug
application submission to the FDA [76].
The prime determinant of efficacy and unexpected toxicity of a drug is how it penetrates
biological barriers such as intestinal wall, or blood-brain barrier (BBB). This is notably true in
central nervous system (CNS) drugs, because candidates that have in vitro efficacy but cannot
penetrate the BBB do not show in vivo efficacy. Thus, the entry of drugs in to the CNS is limited
by the presence of the BBB The BBB effectively isolates the brain from the blood because of the
presence of tight junctions connecting the endothelial cells of the brain vessels. In addition, drug
metabolizing enzymes and efflux pumps, such as P-glycoprotein (P-gp) and the multi-drug18

resistance protein located within the endothelial cells, push out the exogenous molecules from
the brain [77]. As a result of these complications, CNS drugs under development have a
notoriously huge failure rate [78]. Many of these failures perhaps occur due to lack of BBB
permeability. With in vitro tools (such as brain micro dialysis and brain to plasma ratio)
promising drug candidates without effective BBB penetration could be improved at the earliest
stages of development.
A molecule needs to overcome many physicochemical barriers to reach the target site
successfully. The first and foremost important barrier is solubility and permeability. Solubility
and permeability assessments are crucial in ruling in or out the potential of a compound to be a
drug. A preliminary solubility screen will provide information about the solubility of the new
chemical entity (NCE) in solvents well-suited with administration to humans. A compound that
lacks both solubility and permeability is unlikely to become a potential drug candidate even if it
is potent in the primary screening assay [79]. The next barrier is chemical and metabolic
stability. Chemical stability in buffers, simulated gastric and intestinal fluids, and metabolic
stability in plasma, hepatocytes or liver microsomes of different species predicts a compound's
stability in different environments which will be encountered in the human body. After this, the
next step is to define absorption properties of the compounds. Measurement of plasma protein
binding indicates the degree of availability of the free compound in the blood circulation. Only
free drug is active pharmacologically, available for metabolism and can cross the BBB
measurement of protein binding is very important. Metabolism and drug-drug interaction issues
can be detected by screening for inhibition of CYP-450 liver enzymes as CYP-450’s play crucial
role (around 70% of metabolism) in the metabolism of xenobiotics. All these assays allow
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chemists and biologists to obtain actionable information early, allowing them to gain
understanding of structure-activity and structure-property relationships [76].
Figure 1.2 Drug discovery process from identification and validation through to filing of a
compound
.
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A new drug approval is preceded by three steps, discovery, preclinical development, and
clinical trial. A target for a particular disease state is identified, and several new molecules are
designed and screened for toxicity and efficacy in the development stage. The results of the
preliminary pharmacology and toxicology tests contribute to selection of a lead candidate. Once
a lead compound is identified, the normal preclinical development process consists of:
manufacture of drug substance/active pharmaceutical ingredient; preformulation and formulation
(dosage design); analytical and bioanalytical methods development and validation; metabolism
and pharmacokinetics in rodents; toxicology and good manufacturing practice (GMP)
manufacture and documentation of drug product for use in clinical trials [80].
1.6.1. Analytical and bioanalytical methods
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Analytical chemistry applications are found throughout the drug development process
including the initial drug discovery phase. These applications are categorized into
pharmaceutical analysis and bioanalysis. Pharmaceutical analysis is the measurement of an
analyte in a clean sample or formulation, whereas bioanalysis involves the quantification of an
analyte in a biological matrix, such as plasma, serum, urine and tissues [80].
Reliable analytical methods are required to test and qualify in-coming materials, inprocess methods, equipment, formulations, drug substances, and drug products. The analytical
methods are critical for analyzing various formulations that may be investigated for a final
dosage form and are also integral part of quality control in GLP and GMP. In addition, FDA and
International Conference on Harmonisation (ICH) guidelines require stability testing on each lot
of drug subatance and drug product. Therefore, sensitive, robust and specific analytical methods
need to be developed for a variety of materials [80].
Bioanalytical support plays a vital role during the lead optimization stages [81]. Arrays of
bioanalytical methods are required to completely describe the pharmacokinetics behavior in
laboratory animals as well as in humans. Bioanalytical tools can play a significant role for the
progress in drug discovery and development [82]. Physiologic fluids such as blood, serum,
plasma, urine and tissues are analyzed to determine the absorption and disposition of a drug
candidate administered to a test animal. The major goal of the bioanalysis is to assess the over-all
ADME characteristics of the NCE. Often the concentration of the NCE in the biological matrix
changes with time, and perhaps fall below nanogram level, therefore, quantification limits for the
bioanalytical methods should be much lower than those required for analytical methods [81].
Appropriate bioanalytical methods are required to detect drug candidate at low nanogram levels,
at the same time linearly over three orders of magnitude. Effects from the endogenous materials
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(such as plasma proteins) of the biological matrix and stability issues make the accurate analysis
difficult. Methods developed to analyze the pharmacokinetic study samples need complete
separation of the analytes from matrix components [83]. The performance of the bioanalytical
assay can be improved by removing interferences from the matrix trough complex sample
preparation steps, and concentrating the analyte of interest. Common methods of sample
preparation include protein precipitation, liquid-liquid extraction and solid phase extraction [84].
1.6.2. Drug metabolism and pharmacokinetics in drug discovery
Pharmacokinetics, toxicokinetics, and metabolism are key determinants in the selection
of a good drug candidate. Pharmacokinetic parameters are extrapolated from measurements of
drug concentration in the plasma, blood, or other biological matrix over a selected time period.
Pharmacokinetic data provides information that can guide future animal and clinical studies for
the selection of the dose levels and frequency of administration. Oral and intravenous
administrations are compared to determine the oral bioavailability of the drug if an oral route is
anticipated for the clinic [85].
Undesirable pharmacokinetic properties, such as poor absorption, too long or too short
half-life (t1/2), and extensive first-pass metabolism majorly contribute to the failure of many drug
candidates in early stages of drug development programs. The failure rate is very high because of
these reasons. This demonstrates the significance of pharmacokinetics in drug discovery and
development. To be successful a drug candidate needs to posses good bioavailability and a
desirable t1/2. Therefore, a precise estimation and complete understanding of the pharmacokinetic
parameters in the early stages lead to good drug design [86].
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Comprehensive information on the metabolism and pharmacokinetics of the new drug
candidate is required by regulatory agencies [86]. Many of the approved drugs generate
metabolites which possess biological activity. These active metabolites may have different
pharmacology and PK properties than the parent drug. A thorough understanding of the
properties of active metabolite is important for estimating toxicity and therapeutic outcome [87].
It is ideal to assess the metabolism of new drugs in vitro before proceeding to clinical studies. It
is always advantageous to compare the metabolism of the drug in animals and humans in the
initial stages of the drug development process as it can give information about the animal species
selection for toxicity studies. Early information about the enzymes involved in the drug
metabolism is very useful in the design of drug-drug interactions studies [88, 89].
In addition, the invention of liquid chromatography-mass spectrometry and liquid
chromatography-nuclear magnetic resonance techniques resulted in potential to study the
metabolism and PK of new drugs in the early drug discovery stage [90].
1.7. A brief introduction to the present research work
Sigma receptors have recently been identiﬁed as potential targets for the development of
novel therapeutics to treat both cocaine and MA addiction and abuse. Earlier studies have
demonstrated

that

BD1008

(N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-

pyrrolidinyl)ethylamine) a sigma receptor ligand possess anticocaine activity [91]. It was shown
pretreatment with antagonists selective to sigma receptor such as AC927 (N-phenethylpiperdine
oxalate) attenuated methamphetamine induced hyperthermia, dopaminergic and serotonergic
neurotoxicity. Cocaine and MA interact with sigma receptors at physiologically relevant
concentrations. The affinity of cocaine and MA to sigma receptors represents that targeting these
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receptors using selective antagonists will be an effective strategy in the development of novel
medications [92].
This dissertation is primarily focused on the metabolism and pharmacokinetics of novel
sigma receptor antagonists. A series of sigma ligands were evaluated for in vitro and in vivo
biological activity using different ADME tools. The in vitro metabolic stability and the in vitro
half-lives of various analogs will be discussed. Further comprehensive studies were conducted
for the compounds that demonstrated high in vitro metabolic stability. Development of
bioanalytical methods to characterize the preclinical DMPK parameters of the compounds will
be discussed. The dissertation also describes in detail the PK parameters and the factors affecting
the parameters along with their possible routes of biotransformation.
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CHAPTER - 2
METABOLISM AND PHARMACOKINETICS of 3-(4-(4-CYCLOHEXYLPIPERAZIN-1YL)BUTYL)BENZO[D]THIAZOLE-2(3H)-THIONE, A NOVEL MIXED AFFINITY
SIGMA RECEPTOR ANTAGONIST

2.1. Introduction
Cocaine abuse continues as a major problem in the United States due to its powerful
psychological addictive properties [93]. The most common manifestations of drug toxicity are
agitation, kindling (seizures, psychosis), neurotoxicity and stroke damage. Cocaine has been
shown to block the reuptake of dopamine from the synapse by inhibiting the dopamine
transporter and thus causing euphoria [94]. There has been a wide spread research effort to
develop new molecular entities against the rewarding and adverse effects of cocaine by targeting
dopamine, adrenergic and glutamate receptors. However, because of its innumerable action sites,
currently no approved medication is available to treat cocaine toxicity [93]. Therefore new
compounds that can mitigate the actions of cocaine are needed for the treatment of cocaine
addiction [95] Interactions of cocaine with sigma receptors were revealed by the blockade of
locomotor stimulant effects, attenuation of convulsions and rewarding effects of cocaine by
selective sigma receptor antagonists like BD 1008 [96-98]. Also, cocaine has been shown to bind
to sigma receptors with an affinity of about 2 µM, suggesting that sigma receptors are likely to
represent promising targets for the development of anti-cocaine agents [93, 99-102].

25

Sigma receptors, discovered in 1976 by Martin and co-workers, were originally thought to be a
class of opioid receptors; however numerous studies have proved them as unique receptors
distinct from other proteins [93, 99, 102, 103]. To date, two subtypes of sigma receptors have
been identified; sigma-1 and sigma-2, based on the binding and drug discrimination studies [99,
104]. The sigma-1 receptor exhibits high affinity and stereoselectivity for the (+)-isomers of
benzomorphans, in contrast sigma-2 receptor prefers the (-)-stereoisomers. The sigma-1 receptor
was cloned in 1996 [13, 14]. However, the sigma-2 receptor has not yet been cloned, and the
plausible reason may be lack of selective sigma-2 ligands [105, 106]. Sigma receptors are widely
distributed in the CNS with the highest concentrations found in the substantia nigra, and the
cerebellum. These regions are engaged in reward, addiction and motor control. In addition,
sigma receptors are distributed in peripheral organs such as the heart, liver and gastrointestinal
tract [93, 94, 107].
Several studies have shown that many antidepressant and antipsychotic drugs bind to
sigma-1 receptors [104, 108]. Thus selective sigma-1 receptor ligands have been proposed as
potential candidates in the treatment of neuropsychological disorders such as psychotic major
depression, Alzheimer’s disease and Schizophrenia [109]. A major concern with the currently
existing sigma receptor ligands is that most of them are not purely sigma selective. Other than
sigma receptors, they bind to dopamine transporters or NMDA receptors. Thus studies with these
non sigma-preferring ligands can further complicate the understanding of the role of sigma
receptors. Therefore, highly selective sigma ligands play a vital role in the development of
therapeutic agents to treat cocaine abuse and various psychological disorders [11, 107].
Compound CM156 (3-(4-(4-cyclohexylpiperazin-1-yl)butyl)benzo[d] thiazole-2(3H)thione), a cyclohexylpiperazine derivative, is a highly selective sigma receptor antagonist shown
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to possess high affinity for sigma-1 and sigma-2 receptors in the nanomolar and subnanomolar
range [99, 105]. Pharmacological studies demonstrated that CM156 was the best sigma receptor
ligand available to date with highest selectivity and preferential affinity to sigma receptors.
CM156 was shown to significantly attenuate the expression of cocaine induced behavioral
sensitization and place conditioning behaviors possibly by interfering with access of cocaine to
sigma receptors [103]. This study suggests the involvement of sigma receptors in the subchronic
effects of cocaine such as sensitization and the reward properties [107, 110]. Cocaine also
initiates multiple signal transduction pathways that modify the activities of neurotrasmitter
systems such as glutamatergic, dopaminergic and cholinergic systems. These systems can be
regulated by sigma receptors. The novel sigma receptor antagonist CM156 is anticipated to
modulate and reduce the actions of these neurotransmitter systems activated by cocaine.
In order to better understand the pharmacokinetic characteristics of CM156 we developed
and validated a rapid, sensitive and reliable UPLC/MS method for the quantitative determination
of CM156 in plasma. A high sample throughput was achieved by simple sample preparation and
short chromatographic run times under isocratic conditions using this method. The developed
bioanalytical method was validated for specificity, linearity, precision, accuracy and lower limit
of quantification. This method was ultimately used in a pilot study to assess the pharmacokinetic
parameters of CM156 in Sprague-Dawley rats after a single i.v administration of the compound.
Using the data obtained from the pilot study, this method will be further used to investigate the
ADME properties of CM156 in the future.
2.2. Experimental
2.2.1. Chemicals and reagents
27

Compound CM156 (Fig 2.1) was synthesized previously by Christophe Mésangeau et al..
The internal standard (IS), aripiprazole, was purchased from Sigma-Aldrich (St. Louis, MO,
USA). Formic acid was obtained from Mallinckrodt Baker Inc. (Phillipsburg, NJ, USA).
Acetonitrile and water were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Ammonium
formate was purchased from Sigma-Aldrich (St. Louis, MO, USA). Rat plasma was purchased
from Innovative Research (Peary Court Novi, MI, USA). All solvents used were HPLC grade.
2.2.2. Preparation of calibration standards and quality control (QC) samples
The stock solution of CM156 was prepared by dissolving an accurately weighed amount
(0.91 mg in 910 µL) of the compound in water to obtain a final concentration of 1 mg/mL. A 40
µL of the stock solution (1 mg/mL) was transferred to a clean eppendorf tube and to this 960 µL
of acetonitrile was added using a pipette to make a series of working standard solutions, at
concentrations ranging from 50 to 40,000 ng/mL. The IS stock solution (1 mg/mL) was prepared
by weighing 0.63 mg of IS and dissolving in 630 µL methanol and from this primary stock
solution, a working standard solution of IS (3 µg/mL) was prepared by diluting 3 µL of stock
solution with 1 mL of acetonitrile. All stock solutions were stored at -20 °C (Kenmore) and used
within one week of preparation. Calibration standards in plasma were prepared freshly at
concentrations of 5, 10, 50, 100, 500, 1000, 2000 and 4000 ng/mL by spiking blank rat plasma
with the working standard solutions. Blank rat plasma (100 µL) was transferred in to a 1.5 mL
eppendorf tube with a pipette and to this 10 µL of working standard solutions of concentrations
ranging from 50–40,000 ng/mL were added. Quality Control samples were prepared by
transferring 10 µL of working standard solutions of concentrations 100, 4000, 30,000 ng/mL to
an eppendorf tubes containing 100 µL of blank plasma to get 10, 400, and 3000 ng/mL
standards, respectively.
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2.2.3. Sample preparation
A liquid-liquid extraction method was used to extract CM156 from all of the rat plasma
samples including calibration standards and QC samples. Prior to extraction, the rat plasma
samples (100 µL) were thawed at room temperature, spiked with 10 μL of IS (3 µg/mL) and
vortexed for 30 s. The mixture was then extracted with chloroform. A volume of 800 µL of
chloroform was added to each sample, vortexed (VWR Scientific Inc., Radnor, PA, USA) for 15
min and centrifuged at 10,000 x g for 10 min at 4 °C. A fixed aliquot (750 μL) of the organic
phase was transferred using a pipette into an eppendorf tube (Fisher Scientific, Pittsburgh, PA,
USA) and dried in a vacuum oven (Precision Scientific, Winchester, VA, USA) at 25 °C. The
resulting residue was reconstituted with 100 µL of acetonitrile and transferred into a micro
sample insert (Microsolv Technology Corp., Eatontown, NJ, USA) that was pre-installed in a
1.5 mL auto-sampler vial for analysis.
2.2.4. Liquid chromatographic and mass spectrometric conditions
The chromatographic separations were performed on an Acquity UPLC (Waters Corp.,
Milford, MA, USA) equipped with a binary solvent manager, vacuum degasser, temperature
controlled column compartment, and an auto sampler. Chromatographic separations were
performed on a Waters Acquity UPLCTM BEH HILIC column (1.7 μm, 2.1 × 50 mm) using a
mobile phase of 10 mM ammonium formate containing 0.1% formic acid and acetonitrile (10:90,
v/v). The flow rate was set at 0.2 mL/min and this resulted in a total run time of 4 min. The
injection volume was set at 10 µL and the column temperature was held constant at 25 °C. The
mass spectrometric detection was carried out on a Micromass Quattro MicroTM system (Waters
Corp., Manchester, UK) in positive ion mode.
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CM156

Aripiprazole

Fig. 2.1. Structures of CM156 and Aripiprazole (IS)
The following MS parameters were selected for optimal detection of the CM156
compound: a capillary voltage of 4.74 kV; a cone voltage of 36 V; an extractor voltage of 5 V; a
RF lens voltage of 0.5 V; a source temperature of 60 °C and a desolvation temperature of 250
°C. The desolvation and cone gas flows were set at 500 and 72 L/hr, respectively. Quantification
was carried using selected ion monitoring (SIM) for CM156 m/z 390 and IS m/z 448, with a
dwell time of 500 ms. Data acquisition and data processing were performed using Masslynx 4.1
software (Micromass, Manchester, UK) and Microsoft Excel.
2.2.5. Method validation
Analytical method validation assays were performed as per the United States Food and
Drug Administration (US-FDA) Bioanalytical Method Validation Guidance [111]. The
validation of the UPLC/MS method included linearity, lower limit of quantification (LLOQ),
limit of detection (LOD), precision, accuracy, selectivity, recovery, matrix effect and stability.
2.2.5.1. Linearity and sensitivity
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An eight-point calibration curve 5, 10, 50, 100, 500, 1000, 2000 and 4000 ng/mL was
constructed by plotting the ratio of the analyte peak area/ IS peak area versus analyte
concentration. The linearity of the calibration curve was evaluated by linear regression analysis
(MS Excel 2007). The sensitivity of the developed method was determined using LLOQ, the
lowest concentration on calibration curve with a relative standard deviation, (R.S.D.) and relative
error (RE) of less than 20%. The LOD is defined as the analyte concentration which gives rise to
peak whose height is 3 times that of baseline noise.
2.2.5.2. Selectivity
The selectivity of the developed method was investigated for the assessment of potential
interferences of the analyte and IS from endogenous substances. This was evaluated by
comparing the chromatograms of six different lots of blank rat plasma with the corresponding
spiked plasma samples with CM156 and the IS.
2.2.5.3. Recovery and matrix effect
The extraction recovery of CM156 from rat plasma was determined at concentrations of
10, 400, and 3000 ng/mL by comparing the peak area ratios of the compound and IS. Recovery
was calculated by comparing the plasma samples spiked with the compound and IS before
extraction with the plasma samples to which the compound and IS were added after extraction.
Matrix effect is the effect (such as ion suppression) caused by the components other than
the analyte (such as metabolites or endogenous substances) present in the sample on an analytical
method. The matrix effect, due to co-eluting plasma components, was evaluated by spiking six
different lots of blank rat plasma with the QC solutions. The matrix effect of CM156 was
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determined at three QC levels (10, 400, 3000 ng/mL) by comparing the peak area ratios of
standards prepared in plasma with peak area ratios of standards prepared in acetonitrile.

Matrix effect =

x 100

2.2.5.4. Precision and accuracy
The precision and accuracy of the assay were determined by analyzing QC samples at
three different concentrations (10, 400, 3000 ng/mL). To evaluate intra-day accuracy and
precision, QC samples were analyzed in six replicates at each concentration level. The inter-day
accuracy and precision was determined by analysis of QC samples on three consecutive days.
The concentrations were calculated based on calibration curve. The accuracy of the assay was
expressed as relative error (RE),
RE = (Observed concentration−Spiked concentration)/(Spiked concentration)×100%.
The precision of the developed method was expressed as relative standard deviation
(R.S.D.),
R.S.D =

x 100

The intra-day and inter-day precisions were required to be below 15%, and the accuracy
to be within ±15%.
2.2.5.5. Stability
The stability of CM156 in rat plasma was determined by the analysis of six replicates of
QC samples (10, 400, 3000 ng/mL) exposed to various storage conditions including freeze/thaw
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short-term temperature, room temperature, long-term temperature stability and the stability of
CM156 in reconstituted samples (auto-injector stability). For freeze-thaw stability studies,
unprocessed QC samples (100 µL) were subjected to three freeze-thaw cycles. Each sample was
stored at -20 oC (Kenmore) for 24 h and thawed at room temperature, after which the samples
were refrozen for 24 h under the same conditions. At the end of each cycle, the samples were
processed as explained in the section 1.2.3, analyzed and compared with the freshly prepared QC
samples. For the short-term temperature stability study, unprocessed CM156 and IS QC samples
were kept at room temperature for 12 h, which exceeds the routine preparation time of the
samples. At different time points (0, 3, 6 & 12 h) the samples were processed, analyzed and
compared with the freshly prepared QC samples. The post operative stability during storage in
the auto sampler was assessed by re-injecting the samples that were held in the auto sampler at
25 °C for 24 h. To determine long-term stability, QC samples were stored at -20 °C for 1 month
(30 days) which exceeds the time between sample collection and sample analysis.
2.2.6. Physicochemical characterization
2.2.6.1. Determination of the acid dissociation constant (pKa)
pKa of the compound was determined by Potentiometric titrations and ACD/Labs
(Algorithm Version: v12.1.0.3346, Toronto, ON, Canada). For potentiometric titrations, a 1 mM
solution of CM156 was prepared by dissolving 11 mg of compound in 25 mL of water. To this
solution 25 µL of 0.01 M sodium hydroxide solution was added using a 200 µL pipette (Fisher
Scientific, NJ, USA) and the change in pH was recorded using a Mettler Toledo S20 SevenEasy
pH Meter (Fisher Scientific, NJ, USA). The procedure was repeated until a constant pH was
obtained. Thereafter, 25 µL of 0.01 M hydrochloric acid was added continuously and the change
in pH was recorded until a constant value is reached. The titration curves were then constructed
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by plotting the recorded pH versus volume of base/acid added. The intersection point of the
curves was noted as the pKa of the compound.
2.2.6.2. Determination of Log PO/W, Log DPBS, pH 7.4 and Solubility
The octanol/water (pH 6.4) and octanol/PBS (pH7.4) partition coefficients (Log P and
Log D7.4) of CM156 were determined by Stir flask method. For the determination of Log P and
Log D, both phases (octanol, water/PBS) were saturated with one another before the experiment
for 12 h. A portion of CM156 (0.54 mg) was accurately weighed and transferred to a clean glass
vial (4 mL) and then to this 1 mL of the aqueous phase saturated with octanol was added using a
1 mL pipette (Eppendorf, Hamburg, Germany). To the above solution 1 mL of octanol added and
stirred for 24 h on a VWR Dylastir magnetic stirrer (Bridgeport, NJ, USA) using a magnetic
bead. An aliquot of 100 µL of the aqueous phase was then analyzed by UPLC/MS/MS.
Calibration curves prepared in phosphate buffer and water were used for the estimation of the
concentration in aqueous phase. For the preparation of calibration curve, 0.91 mg of compound
was dissolved in 910 µL of acetonitrile to get a stock solution of 1 mg/mL. From this solution
calibration standards were prepared by diluting with buffer.
The solubility of CM156 was determined in distilled water and in phosphate buffer saline
(pH 7.4) using the standard shake flask method. An excess amount (20 mg) of CM156 was added
to 100 µL of the solvent in 2 mL glass vials. The vials were constantly agitated (100 rpm) at
room temperature (25 °C) for 24 h in reciprocating shaking water bath (Precision Scientific, VA,
USA) for uniform mixing. After 24 h, the samples were collected using a pipette and centrifuged
at 10,000 x g for 5 min. The supernatant was then analyzed using UPLC/MS/MS.
2.2.7. Metabolic stability of CM156 in rat, mouse and human liver microsomes
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Biotransformation of xenobiotics is divided into two types: phase I (hydrolysis,
oxidation, and reduction) and phase II (conjugation). The cytochrome P450 (CYP 450) enzyme
superfamily is predominantly responsible for phase I metabolism, and phase II conjugation is
mainly catalyzed by UDP-glucuronyltransferases [112, 113]. CM156 was incubated with liver
microsomes from male rats, mouse and humans in Tris buffer (pH 7.4). The standard incubation
mixture contained 0.1 M MgCl2, 1 mM NADPH regenerating system (NADP 1 mM, glucose-6phosphate 5 mM, and glucose-6-phosphate dehydrogenase 1 Unit/mL), 1 mg of microsomal
protein and 5 µM substrate. The final volume was adjusted to 1 mL with the appropriate amount
of buffer. Incubations were performed at 37 °C and 100 rpm in shaking water bath (Precision
Scientific, VA, USA) for 30 min. Metabolic stability was assessed quantitatively by measuring
the disappearance of the substrate during the incubation period. Reactions were initiated by the
addition of NADPH regenerating system after 5 min of pre-incubation and terminated at
predetermined time points (0, 5, 10, 15, 20 and 30 min) by the addition of equal volumes (1 mL)
of ice-cold acetonitrile. Samples were vortexed for 30 sec, then centrifuged at 10,000 x g for 10
min finally the supernatant was analyzed by UPLC/MS/MS. The separation was achieved on a
C18 (2.1 mm x 50 mm, 1.7 µm) column by elution with mobile phase consisting of 0.1% formic
acid in water and acetonitrile (23:77 v/v). The mobile phase was pumped at a flow rate of 0.15
mL/min. For Phase II metabolism studies, CM156 was incubated with rat liver microsomes in
presence of UDPGA (Sigma-Aldrich, USA). The substrate concentration was 5 µM. Incubations
of CM156 without NADPH and UDPGA were run as control.
2.2.8. Plasma protein binding studies
The extent of protein binding of CM156 in rat plasma was determined by ultrafiltration
using the Centrifree micropartition system (Amicon, MA, USA) at specific concentrations of 300
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and 2000 ng/mL. A stock solution (1 mg/mL) of CM156 was prepared by dissolving 0.45 mg in
450 µL. From this stock solution working standards of concentrations 3 and 20 µg/mL were
prepared by diluting with buffer. The plasma samples of concentrations 300 and 2000 ng/mL
were then prepared by diluting the working standards with rat plasma. The samples (500 µL)
were then transferred using 1 mL pipette to Centrifree® devices and incubated at 37 °C. After 15
min of incubation, the plasma samples were subjected to centrifugation in Beckman rotor
centrifuge at 1500 x g for 10 min and ultrafiltrates were collected in to a 1.5 mL eppendorf tube
from the Centrifree devices using a pipette. To an aliquot (100 μL) of the ultrafiltrates, 10 μL of
internal standard was added and analyzed by UPLC/MS/MS. A control experiment was done
with ammonium acetate buffer (pH 7.4) to estimate the nonspecific binding of the substrate.
Protein binding was calculated using the following equation.

Plasma protein binding (%) =

2.2.9. In vivo pharmacokinetics in rats
The developed and validated UPLC/MS method was used to determine the
pharmacokinetic parameters of CM156 in rats after the intravenous administration of the
compound. The animal experimental protocol was approved by the Institutional Animal Care and
Use Committee (IACUC) of the University of Mississippi. Six male Sprague-Dawley rats (180200 g) were obtained from Harlan Laboratories (Indianapolis, IN, USA), which had already
inserted polyethylene cannulas into the right jugular vein. The rats were housed in metabolic
cages and allowed free movement and access to water during the whole experiment. The rats
were fasted for 12 h before dosing and for the first 4 h after dosing. A small amount of CM156
(4 mg) was dissolved in saline (2 mL, measured using a pipette) for i.v administration. A single
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intravenous bolus (0.5 mL) of CM156 was injected at a dose of 5 mg/kg through the jugular vein
cannula in less than 30 s. The formulation was filtered through a 0.2 µm filter prior to
administration. The i.v. solution was administered via the jugular vein cannula using a syringe
(1 mL), after which the cannula was flushed with 0.2 mL heparinized saline to ensure complete
administration of the dose.
Blood samples were collected using a syringe (1 mL) through the indwelling cannula into
heparinized micro centrifuge tubes at 0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 360,
480 min. An initial blood volume of 0.05 mL was withdrawn to clear the line of heparinised
saline. A fresh syringe was then used to withdraw a 0.25 mL blood sample that was placed in a
micro-centrifuge tube. After each blood sampling, 0.2 mL of a heparin-saline (10 I.U./mL)
solution was used to flush the catheter. Blood samples were immediately centrifuged at 10,000 ×
g for 20 min at 4 °C using an Accuspin Micro 17R centrifuge (Fisher Scientific, Pittsburgh, PA,
USA). The plasma was separated from the solid components and transferred into a 1 mL micro
centrifuge tubes. These samples were frozen (Kenmore) at -20 °C until they were analyzed. The
pharmacokinetic parameters were calculated by non compartmental analysis using WinNonlin
5.2 (Pharsight, Mountain View, CA, USA).
Urine sampling
A solution of CM156 was intravenously administered to rats (n=6) at a dose of 5 mg/kg.
Urine was collected in to BD vacutainer containers at specified time intervals (0-2, 2-4, 4-8 h)
after the administration of compound. Blank urine (urine before administering the test
compound) that was collected in to the graduated urine collection tube of the metabolic cage was
also transferred to BD vacutainer®. The volume of urine collected in graduated containers was
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noted during each time interval and kept frozen at -20 °C until analyzed. Urine samples were
analyzed by LC/MS/MS for the quantification of CM156 in urine and to detect phase I and phase
II metabolites.
2.2.10. Brian to plasma ratio
Brain to plasma ratio gives information about the extent of penetration of the compound
into the brain [114]. For the determination of brain to plasma ratio of CM156, brains were
thawed at room temperature and transferred to a 20 mL glass vial. To this 3 mL of water was
added and the tissues were homozinized using a tissue homozinizer, (Tekmark, OH, USA). The
homogenate was then transferred to a fresh eppendorf tube (1.5 mL) and centrifuged at 10,000 x
g for 10 min to remove the entrapped air. An aliquot (100 µL) of the homogenate was transferred
using a pipette in to a clean eppendorf tube, to this 10 µL of IS was added and vortexed for 30 s.
The mixture was then extracted with chloroform (800 µL) by vortexing for 10 min and
centrifuged using an Accuspin Micro 17R centrifuge at 10,000 x g for 7 min. A fixed aliquot
(725 µL) of the lower organic layer was collected after centrifugation and subjected to
evaporation in a vacuum oven (Precision Scientific, Winchester, VA, USA). The residue was
reconstituted in 100 µL of water and aliquot of 5 µL was injected into the UPLC/MS/MS for the
quantification. The concentration of CM156 in brain samples was then determined from standard
curves prepared in blank brains (Pel-Freeze, AR, USA).
Calibration curve
The preparation of calibration standards is similar to standards prepared in plasma,
explained in section 1.2.3. Briefly, for the construction of a standard graph seven concentrations
0.1, 0.5, 1, 2, 5, 7 µg/mL were used. The standards were prepared in blank brain samples by
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spiking 10 µL of solutions of concentrations 1, 5, 10, 20, 50 and 70 µg/mL. To this mixture, 10
µL of the IS (3 µg/mL) was added, vortexed for 30 s and extracted with choloroform (800 µL). A
fixed aliquot of the organic phase (725 µL) was separated using a pipette after centrifugation and
was evaporated to dryness in a vacuum oven. The dried samples were reconstituted with 100 µL
of water and analyzed using UPLC/MS/MS.
Atenolol and Imapramine were used negative and positive controls. Atenolol was
administered to rats at a dose of 10 mg/kg intraperitoneally and B/P was determined at 30 min
after the administration of the compound. Imipramine was administered at a dose of 20 mg/kg
intraperitoneally and B/P ratio was determined at 3 h after administration of the compound. For
the assessment of B/P ratio of atenolol and imipramine, brain and plasma samples were extracted
(same as CM156 extraction procedure) with acetonitrile and analyzed using UPLC/MS/MS.
2.2.11. Identification of urinary metabolites of CM156 by tandem mass spectrometry
The metabolism of the CM156 in rats was characterized using liquid chromatography
(UPLC)/tandem mass spectrometry (MS/MS) with precursor ion and constant neutral loss scans
followed by product ion scans [115]. Tandem mass spectrometry is capable of rapidly identifying
metabolites with characteristic sub-structures without the necessity of baseline separation of each
compound. The identification of metabolites using MS/MS is based on the assumptions that
most metabolites retain much of their original scaffolding and undergo the same fragmentation
pattern as the parent compound. The structures of possible metabolites are characterized by
interpreting their product ion spectra or comparing the product ion spectra and LC retention
times with authentic standards [115, 116].
The approach can be summarized as follows:
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(1) to obtain a product ion scan of a parent drug
(2) to conduct precursor ion scans of the selected product ions obtained in previous step. This
step provides the molecular ion information for the metabolites;
(3) to obtain product ion scans of the identified metabolites. This step gives the information for
characterization of the metabolite structures.
2.2.11.1. Liquid chromatography-triple quadrupole mass spectrometry
All samples were analyzed for the presence of phase I and phase II metabolites on an
Waters Acquity UPLCTM BEH C18 column (1.7 μm, 2.1 × 50 mm). Injection volume was 5 µL.
The mobile phase consisted of 0.1 % formic acid in water: acetonitrile. The gradient program
was 0 to 3 min at 5 to 10 % B, 3 to 10 min at 10 to 22% B, 10 to 12 min at 22 to 50% B, 12 to 14
min at 50 to 5% B and 14 to 16 min at 5% B. The MS detection was carried out on Micromass
Quattro microTM system (Waters Corp., Manchester, UK). LC/MS/MS with positive electrospray
ionization in various scan modes such as precursor (parent) ion scan, constant neutral loss scan
(NLS), multiple reaction monitoring (MRM) and daughter (product) ion scan were used for the
identification of phase I and phase II metabolites.

2.3. Results and discussion
2.3.1. Chromatography
Because CM156 is a polar compound, it did not retain well on a traditional C18 column.
Consequently, based on the retention time of the compound and the separation efficiency of the
column, an Acquity BEH HILIC column was selected to develop the UPLC assay. Aripiprazole
was chosen as the IS due to its similar chromatographic characteristics, strong mass response in
40

positive ESI mode and lack of endogenous interferences at m/z 448. Different concentrations of
formic acid (0.05%, 0.1% and 0.2%) in aqueous phase were tested to improve the
chromatographic peak shapes and increase the MS response. The results indicated that a solution
of 0.1% of formic acid improved the peak shapes and MS response of CM156 and the IS, but
was unable to produce baseline separation of the two compounds. To improve the separation,
various amounts of ammonium formate (1, 5, 10 mM) were added to the aqueous phase. Baseline
separation of analyte and IS is very important when LC/MS is used for the analysis. This avoids
the interferences caused due to possible ion suppression or enhancement effects [117]. We
determined that 10 mM ammonium formate produced the best separation of the two compounds.
Acetonitrile was chosen as the organic phase because it produced a higher analyte response,
which led to lower background noise compared to methanol. The selected mobile phase
consisted of 10 mM ammonium formate buffer solution containing 0.1% formic acid and
acetonitrile (10:90 v/v). This was pumped at a flow rate of 0.2 mL/min for analysis, the retention
times for CM156 and IS were 2.6 and 2.1 min and a run was completed in 4 min. As protein
precipitation alone did not result in the complete purification of the plasma samples, a single-step
liquid–liquid extraction was adopted to achieve high recovery of the analytes with no
interferences in minimal time. Chloroform was selected as the extraction solvent because it
showed invariable recoveries ranging from 86.3 to 105.9% in the concentration range from 5 to
4000 ng/mL.
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Acetonitrile

%Recovery of
CM156
41

Chloroform

96

Dichloromethane

34

Ethyl acetate

54

Methyl tert-butyl ether

55

Solvent

Table 2.1: Recovery of CM156 in various solvents
Conc (ng/mL)

Recovery
(%) ± SD

10

94.5 ± 4.3

400

92.0 ± 6.1

3000

89.3 ± 6.3

Table 2.2: Recovery of CM156 from spiked rat plasma
2.3.2. Mass spectrometry
Electro spray ionization positive ion monitoring mode was chosen for the measurement
of CM156 in rat plasma samples. Because CM156 was a basic compound, it captured the protons
easily and gave maximum detector intensity in the positive ionization mode. Upon the direct
injection of CM156 and the IS in to the mass spectrometer, singly protonated ions were found to
be the most sensitive ions [M+H]+. Therefore the molecular ions at m/z 390.09 and m/z 448.03
were selected as the target ions in SIR for CM156 and the IS respectively. Full mass scans of
CM156 and the IS are shown in Fig. 2.2
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Fig. 2.2. Full mass scan of CM156 (A) and Aripiprazole (IS, B)
2.3.3. Method validation
2.3.3.1. Linearity of calibration curve and lower limit of quantification
Calibration standards of CM156 at concentration levels of 5, 10, 50, 100, 500, 1000, 2000
and 4000 ng/mL were extracted and assayed. A typical regression equation for the calibration
curve was: y = 0.047x + 0.1997
Where y represents the peak area ratios of CM156 to the IS and x represents plasma
concentrations of analyte. The calibration curve was found to be linear over the concentration
range from 5 to 4000 ng/mL resulting in a correlation coefficient r2 > 0.995. The Lower limit of
quantification for CM156 in plasma was 5.0 ng/mL with precision (R.S.D.) below 20% and
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accuracy (RE) within ±20%. This quantification was found to be sensitive enough to investigate
the pharmacokinetic behavior of CM156 in preclinical studies. The LOD was estimated at 2
ng/mL.

Analyte peak area/IS peak area

300

y = 0.06x + 1.44
R² = 0.99

250
200
150
100
50
0
0

1000

2000
3000
Conc ng/mL

4000

5000

Fig. 2.3. Calibration curve of CM156.
2.3.3.2. Selectivity
The selectivity of the assay was assessed by comparing the chromatograms of six
different lots of blank rat plasma with the corresponding spiked plasma. The representative
chromatograms of blank plasma, plasma spiked with CM156 (400 ng/mL) and IS (300 ng/mL)
are presented in Fig. 2.4. No interference were observed at the retention times of the CM156 (2.6
± 0.1 min) or the IS (2.1 ± 0.1 min).
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Fig. 2.4. Representative SIR chromatograms for CM156 and Aripiprazole (IS) in rat plasma: (a)
blank plasma sample; (b) blank plasma sample spiked with CM156 at LLOQ and aripiprazole
(IS) at 300.0 ng/mL; (c) rat plasma sample obtained at 1.0 hr after a single intravenous injection
at a dose of 5 mg/kg.
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2.3.3.3. Precision and accuracy of the assay
The accuracy and the intra and inter-day precision of the analytical method were
evaluated with six replicates at three different concentrations 10, 400 and 3000 ng/mL. The
intra-day precision ranged from 3.5% to 4.4% and the inter-day precision ranged from 2.6% to
5.6%. The accuracy of the assay ranged from -6.5 to 5.0%. The data obtained was within the
acceptable limits and the method was precise and accurate. Table 2.3. summarizes intra- and
inter-day precision and accuracy.
Spiked
conc.
(ng/mL)

Intra-day precision and accuracy
R.S.D
(%)

R.E
(%)

10

Measured
concentration
(mean ±SD, ng/mL)
10.5 ± 0.4

3.8

5.0

400

411.0 ± 14.5

3.5

2.8

3000

2932.4 ± 130.2

4.4

-2.3

Inter-day precision and accuracy
Measured
concentration
(mean ±SD, ng/mL)
9.4 ± 0.5

R.S.D. R.E
(%)
(%)
5.6

-6.5

404.3 ± 10.7

2.6

1.1

2993.3 ± 88.7

2.9

-0.2

Table 2.3 Precision and accuracy data for CM156 in rat plasma
2.3.3.4. Recovery and matrix effect
The extraction recoveries of CM156 from rat plasma at the concentrations of 10, 400 and
3000 ng/mL were 97.2 ± 5.6%, 100.4 ± 6.9% and 101.5 ± 7.8%, respectively. The extraction
recovery of IS from rat plasma was 58.2% at a concentration of 300 ng/mL. Recovery of the
internal standard was consistent and reproducible. The matrix effects of CM156 were between
90% and 105%. The matrix effect of IS was 98.5%. There is no difference between the peak
areas of standards prepared in plasma and peak areas of standards prepared in acetonitrile. These
results indicated that no co-eluting substances influenced the ionization of the analyte and IS.
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2.3.3.5. Stability
The stability of CM156 was evaluated under different conditions at three concentrations
(10, 400 and 3000 ng/mL). The results indicated that CM156 was stable in rat plasma stored at
room temperature for 12 h, at -20 °C for 1 month and during three freeze/thaw cycles. The
compound was also found to be stable in reconstituted samples when stored for 24 h in the auto
sampler at 25 °C. The stock solutions of CM156 and IS were stable for at least 6 h at room
temperature and for one week at -20 °C. Results of the stability studies are shown in Table 2.4.

Storage condition

Concentration (ng/mL)

R.S.D.
(%)

RE
(%)

Spiked
10
400
3000

Measured
9.2 ± 1.1
406.4 ± 8.8
2879.4 ± 209.8

12.3
2.2
7.3

-6.6
1.6
-4.0

Long term for 30 days (-20 °C)

10
400
3000

11.2 ± 0.9
394.8 ± 17.8
2879.4 ± 243.1

8.6
4.5
7.8

12.8
-1.3
3.9

Short term for 12hr (25 °C)

10
400
3000

8.6 ± 0.7
4.3.6 ± 9.2
2879.4 ± 145.2

8.3
2.2
5.0

12.3
2.3
4.0

Auto sampler for 24hr (25 °C)

10
400
3000

10.0 ± 0.2
404.4 ± 4.7
2901.1 ± 59.2

3.0
1.2
2.0

2.2
1.1
-3.3

Three freeze thaw cycles

Table 2.4. Stability data for CM156 in rat plasma at various storage conditions
2.3.6. Physicochemical characterization
Drugs acting on the CNS must cross the Blood brain barrier and the BBB penetration of
drug candidates can be assessed by determining their physicochemical properties like Log P, Log
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D and pKa. The pKa of the compound CM156 was 9.2 indicating that the compound is weakly
basic in nature and it exist in equilibrium between its charged and neutral states under
physiological conditions. The ideal pKa for CNS compounds is between 4-10 [118].
The partition coefficient (Log P) is a constant and is defined as the ratio of concentration
of a neutral compound in aqueous phase to the concentration in an organic solvent. Log D is the
log distribution coefficient at a particular pH. Log D varies with pH. Log D at pH 7.4 is often
gives an indication of the lipophilicity of a compound at the pH of blood or plasma. The log P
o/w (pH 6.4) and log D 7.4 of the compound were 0.5 and 1.6, respectively. This indicates that the
compound distributes in to both octanol and water phases in appreciable amounts.
2.3.7. In vitro metabolism studies
Metabolic stability of CM156 was investigated in liver microsomes from mouse, rat, and
human. Half-life was determined from the linear portion of the curve (Fig.2.5) with a mono
exponential decay using GraphPad Prism 5. The compound was highly unstable in liver
microsomes and degraded more quickly in mouse and rat liver microsomes compared to human
liver microsomes in the presence of NADPH. The half-lives were found to be 3.3, 4.1 and 4.6
min in mouse, rat and human liver microsomes, respectively. To evaluate the metabolism by
phase II conjugation, UDPGA was introduced in to the microsomal incubation mixture. There
was no major difference in the metabolic stability of CM156 in the presence or absence of
UDPGA as evidenced by comparable half-lives during incubation with phase I and II systems
(Table 2.5). These results further confirm that phase I enzymes are predominantly responsible for
the in vitro metabolism of CM156. The poor metabolic stability of CM156 might be ascribed to
the weak C-N bond between the benzo[d]thiazole-2(3H)-thione ring and the cyclohehylpiperzine
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moiety in addition to the high susceptibility of the sulfur atom in the thiazole-2(3H)-thione
moiety to metabolism.

Rat

Half-life
(min) Phase I
4.6

Half-life
(min) Phase II
5.0

Mouse

3.3

3.9

Human

4.1

4.6

Species

Table 2.5. Metabolic stability of CM156 in rat, mouse and human liver microsomes

Log Percent Drug Remaining

100
Rat
Human
Mouse
10

1
0

10

20

30
40
Incubation Time (min)

50

60

70

Fig. 2.5. Plot of the incubation time (min) vs percent drug remaining
2.3.8. Plasma protein binding
Compound CM156 was found to be 82% bound to rat plasma proteins at three different
concentrations. The protein binding did not change with increase in concentration of the
compound indicating that the binding was independent of concentration. The nonspecific binding
of the compound to the components of Ultracentrifree® was less than 0.2%, indicating that
ultrafiltration is a suitable method for protein binding studies of CM156.
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Conc of CM156
(ng/mL)

% Binding

300

82.8

1100

82.3

2000

81.6

2.3.9. Pharmacokinetics of CM156 in rats
After the administration of a single i.v. dose of 5 mg/kg, the Cmax of CM156 was 1.3 ±
0.2 µg/mL. The plasma concentrations declined very quickly indicating a rapid distribution of
the novel sigma receptor ligand into the tissues. The distribution of CM156 was found to be
extensive (9.6 L/kg) indicating high tissue binding. This is probably due to the hydrophobic
nature of the compound. The log D Oct/PBS (pH 7.4) was 1.6. Despite its high Vd, CM156
exhibited a short half-life (65 min). The rapid elimination from the systemic circulation i.e, a
high clearance (6.2 L/h/kg) might be a plausible reason for the half-life. This is supported by its
extremely poor microsomal metabolic stability and high hepatic intrinsic clearance. The amount
of compound excreted unchanged in urine was less than 0.1% and this further suggests that high
clearance is the result of extensive liver metabolism. The mean plasma concentration-time
profile is shown in Fig. 2.6. The pharmacokinetic parameters are presented in Table 2.6.

Fig. 2.6. Mean plasma concentrations of CM156 after a single intravenous injection of to rats at
a dose of 5mg/kg (n=6)
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Parameter

Mean ± SD

t1/2 (hr)
Cmax (µg/mL)
AUC0→∞ (µg min/mL)
Vd (L/kg)
CL (L/h/ kg)
MRT (min)

1.1 ± 0.4
1.3 ± 0.2
48.1 ± 6.3
9.6 ± 1.4
6.2 ± 1.0
90.1 ± 13.0

Table 2.6 Pharmacokinetic parameters of CM156 in rats following a single intravenous dose of 5
mg/kg (Mean±SD, n=6).

2.3.10. Brain to plasma ratio
BBB separates the blood compartment from those within the brain and it is the
permeability barrier for transport from and into the CNS. Adequate exposure of the drugs in the
brain is essential for the treatment of CNS diseases. BBB greatly impedes entry of all molecules
from blood to brain, except small and lipophilic molecules or those that enter the brain through
an active transport mechanism with nutrients, and cofactors. B/P ratio is a common approach in
CNS drug discovery process to estimate the ratio of drug concentration in brain and plasma. It
provides a measure of partitioning of drug in to brain from blood and the results are expressed as
a brain/plasma ratio [119]. Brain to plasma ratio of CM156 was determined at 10 and 20 min
after the i.v. administration at a dose of 5 mg/kg. Fig 2.7 shows the calibration curve of CM156
in rat brain. The brain concentrations are 6-7 times higher than the plasma concentration. The
results are in agreement with the pharmacokinetic profile, with a reported apparent volume of
distribution being 9.6 ± 1.4, indicating considerable uptake of the drug into tissues. The brain to
plasma (B/P) ratio of CM156 at 10 and 20 min were found to be 6.5 and 7.2, respectively. The
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high B/P ratio of CM156 suggests that it is freely crossing the BBB and accumulating in the

Analyte area/IS area

brain tissues. The B/P values at 10 and 20 min are represented in table 2.7.
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Figure 2.7: Calibration curve of CM156 in rat brain tissues
Concentration

Dose
(mg/kg)

Time
(min)

Brain (µg/gm)

Plasma (µg/mL)

5

10

6.3

0.96

6.5±0.19

5

20

3.8

0.52

7.2±0.02

B/P ratio

Table 2.7. Concentrations of CM156 in plasma and brain; ratio between brain and plasma
concentrations (n=3)
2.3.11. Identification of urinary metabolites
Compound CM156 produced a protonated molecular ion, [M+H]+ at m/z 389, consistent
with the molecular formula C21H22N3S2. The MS/MS spectrum of the m/z 389 generated a series
of product ions at m/z 221, 169, 142, 124, 86, 55. The major product ion at m/z 221 was formed
due to the loss of 168 (loss of cyclohexylpiperazine moiety). The product ion at m/z 169 and 86
corresponds to benzo[d]thiazole-2(3H) -thione and cyclohexyl groups, respectively. The parent
compound has a labile bond between the carbon atom of the 3-butylbenzo[d]thiazole-2(3H)52

thione group (m/z 221) and the nitrogen of the cyclohexylpiperazine moiety (m/z 168). These
groups with their molecular weights are represented in fig. 2.8. This C–N bond is highly
susceptible to fragmentation, resulting in formation of two major fragments: a stable carbocation
4-(2-thioxobenzo[d]thiazol-3(2H)-yl)butan-1-ylium representing the major peak (m/z 221.9) in
the MS/MS spectrum and a neutral fragment (m/z 168) corresponding to cyclohexylpiperazine
moiety.
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Fig.2.8. Product ion spectra and structure of parent compound, CM156
As the metabolites generally share a common structure with the parent compound, the
initial search for the metabolites of CM156 in urine samples was conducted by a precursor ion
scan using the major fragment ion of the parent compound, m/z 221. In addition to this, m/z 176
(dehydroglucuronicacid) and m/z 168, 80 were used to perform the neutral loss scan to detect the
phase II metabolites; glucuronide and sulfate conjugates. The precursor ion scan of the rat urine
sample yielded ions at m/z 390, the parent compound, m/z 406, 307, 321 and 375. The neutral
loss scan of 176 showed a single peak with the parent ion of m/z 582.
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With the aid of the precursor ion scan at m/z 221 and the neutral loss scan of 176 from
the urine samples, we were able to identify the major metabolites of CM156. The interpretation
of the product ion spectra of the ions with m/z 389 (CM156), 375 (M1), 307 (M2), 321 (M3),
406 (M4), 582 (M4-Glu) is explained as follows.
The protonated molecular ion of metabolite M1 showed an intense signal at m/z 374, 16
Da lower than the parent compound (CM156) suggesting the replacement of the sulfur atom with
oxygen. The MS/MS spectrum of M1 (m/z 374) yielded a series of characteristic product ions at
m/z 292, 263, 205, 182, 164. The product ions at m/z 292 and 205 were formed due to the loss of
the cyclohexyl and cyclohexylpiperazinyl moieties, respectively. Nevertheless, the other
substructures of M1 could not be identified with the product ion spectrum. M1 had similar
product ions scan and it co-eluted with the authentic standard on LC. Based on its characteristic
product ions and LC retention times M1 was identified and confirmed as oxidative metabolite of
CM156. Fig.2.9. represents the daughter ion spectrum of urine sample (a) and synthetic standard.
(b).
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Fig. 2.9. (a). Product ion spectra of metabolite M1
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Fig. 2.9.(b). Product ion spectra of authentic standard
The [M+H]+ ion of M2 at m/z 307 was generated due to the loss of a cyclohexyl ring.
The major fragmentation observed was probably due to the loss of the fragment 168 to form an
abundant daughter ion at m/z 221. The other product ions identified were m/z 169, 124, 142, and
55. The fragment ions of M2 at m/z 221 and 169 confirm the proposed structure of M2.
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Fig. 2.10. Product ion spectra and proposed structure of metabolite M2
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Metabolite M3 was proposed as oxo metabolite of M2, as its molecular weight was 14 Da
higher than M2. The MS/MS spectrum of M3 showed structurally significant product ions at m/z
307, 221, 169, 142, 55. The similarity in the product ions of M2 and M3 also suggests that M3 is
a substructure of M2.
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Fig. 2.11. Product ion spectra and proposed structure of metabolite M3
The [M+H]+ ion at m/z 406 was 16 Da higher than that of the parent compound,
suggesting that M4 was a mono hydroxylated metabolite. The MS/MS spectrum of m/z 406
yielded a series of product ions at m/z 390, 307, 221, 194, 169, 100, 55. The ion at m/z 307 was
formed due to the loss of cyclohexyl ring. The ions at 221, 195 and 169 were generated due to
the sequential losses of cyclohexylpiperazinyl, ethyl and butyl cyclohexylpiperazinyl moieties,
respectively. Product ions at m/z 307, 221, 169 common to M2, M3 and M5 suggests that the
hydroxyl group of M4 is not located on the 3-(4-(pipeazin-1-yl)butyl)benzo[d]thiazole-2(3H)thione group (the unchanged substructure) of CM156. In addition, the specific product ions m/z
307 and 100 confirmed that hydroxyl group is present on the cyclohexyl ring, however the exact
location of the on the ring could not be identified.
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Fig. 2.12. Product ion spectra and proposed structure of metabolite M4
The metabolite M5 was 176 Da higher than that of M4. The MS/MS spectrum of M5
showed a series of fragment ion at m/z 406, 307, 221, 169, 142, 113, 55. These product ions
were similar to M4, confirming that metabolite M5 was glucuronide conjugate of M4.
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Fig. 2.13. Product ion spectra and proposed structure of metabolite M5
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Metabolites were identified by LC/MS/MS operated in various scan modes and
confirmed (oxidative metabolite) by comparison of their retention times on HPLC with synthetic
standards. FMO’s and CYP3A4 are assumed to be involved in the metabolism of CM156. The
representative chromatograms are shown in Fig. 2.14.
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Fig. 2.14.Chromatograms of (A) CM156, (B) Metabolite M1, (C) Metabolite M2, (D) Metabolite
M3, (E) Metabolite M4, (F) Metabolite M5
A total of 5 metabolites: 4 phase I metabolites and 1 phase II metabolites (M1, M2, M3,
M4, M5) were identified in rat urine. This shows that the clearance of CM156 in rats involved
both phase I and phase II pathways. The major routes of metabolism involved oxidation at sulfur
(M1), loss of cyclohexyl ring attached to the piperazinyl nitrogen (M2, M3), hydroxylation and
subsequent conjugation with glucuronic acid (M4, M5). The formation of M1 and also absence
of aromatic hydroxylated metabolite suggests that benzothiazolethione moiety is more vulnerable
to oxidation rather aromatic hydroxylation.
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Based on the structures of metabolites, a plausible scheme for the biotransformation pathway of
CM156 in rats is shown in Fig.2.15.
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2.4. Conclusions
A bioanalytical method was developed and validated for the determination of CM156 in
rat plasma. The experimental pKa and Log D values indicates that CM156 posses desirable
physicochemical properties that are required for the BBB penetration. Based on microsomal
metabolic stability studies, CM156 was found to be less stable in in vitro in rat and mouse liver
microsomes compared to human liver microsomes. Intravenous pharmacokinetics in rats
demonstrated its high distribution in to tissues. This could be a promising property for a
compound acting on CNS. This is also further confirmed by its high b/p ratio. The amount
excreted in urine was found to be less than 0.1 %. The possible in vivo biotransformation
pathway was identified using Tandem mass spectrometer. Four phase I and one phase II
metabolite of CM156 were identified using UPLC/MS/MS. The involvement of FMO was
indicated through enzyme inhibition by methimazole, heat inactivation, and protection against
heat inactivation by NADPH.
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CHAPTER-3
DRUG METABOLISM AND PHARMACOKINETICS OF 3-(4-(4CYCLOHEXYLPIPERAZINE-1-YL)PENTYL)-6-FLUOROBENZO[D]THIAZOLE2(3H)-ONE, A NOVEL SIGMA RECEPTOR LIGAND WITH IMPROVED
METABOLIC STABILITY
3.1. Introduction
Methamphetamine (MA) is a psychomotor stimulant, neurotoxic addictive and the second
most illicit drug abused worldwide [120-122]. It can be synthesized readily from over the
counter drugs. Current surveys estimate that around 15-16 million people have abused
methamphetamine [123]. The short-term stimulant effects of MA include euphoria,
hyperthermia, enhanced energy, increased physical activity and decrease appetite [123, 124].
Repeated MA use results in addiction, psychosis, changes in brain structure and function
involving terminals of dopamine and serotonin neurons, memory loss, neurodegeneration [121,
125, 126]. Multiple mechanisms contribute to the meth-induced neurotoxicity include oxidative
stress due to formation of oxygen and nitrogen reactive species, abnormal dopamine and
glutamate transmission, mitochondrial dysfunctions, apoptosis, astroglial and microglial
activations, brain hyperthermia [121, 127-129]. However, the mechanisms underlying these
neurodegenerative effects are not yet thoroughly understood. Methamphetamine enhances the
synaptic levels of norepinephrine, dopamine (DA), and serotonin (5-HT) by reversing the
transport that facilitates excess release of these mono amines and also by preventing their
reuptake [125, 130]. Currently, there is no FDA approved pharmacotherapy to treat the harmful
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effects of MA [123, 131]. Various effects of methamphetamine are supposed to be related to its
interaction with monoamine transporters. Nevertheless, methamphetamine also has affinity for
both σ1 and σ2 receptors and interacts with σ receptors at physiologically attainable
concentrations suggesting their role in methamphetamine’s effects [132-135]. Sigma receptors
are unique proteins discovered by Martin et al. in 1976 [136-138]. Based on the specific
pharmacological and functional characteristics, sigma receptors are divided into two
subtypes, σ1 and σ2 [139-141]. The sigma-1 receptor is a 25-29 kDa protein with 223 amino
acids and was cloned in 1996 [142-144]. It is localized in various organs such as liver, heart,
gastrointestinal tract and limbic system of brain is particularly rich in these receptors [140, 144].
The sigma-2 receptor is an 18-21 kDa protein, which is not yet been cloned [141, 145, 146].
Sigma receptors are distributed in the organs that mediate the actions of METH such as
dopaminergic system in the brain and the activation of these receptors results in the synthesis and
release of dopamine [132, 147, 148]. Sigma receptors are distributed in the organs that mediate
the actions of METH such as dopaminergic system in the brain and the activation of these
receptors results in the synthesis and release of dopamine [132, 147, 148].
Currently, sigma receptor antagonists are being investigated as potential agents for
METH abuse and toxicity; targeting these receptors can become a promising therapeutic
approach in treating addiction to METH [134, 135]. In addition, the neurotoxic and stimulant
effects of METH were attenuated by sigma receptor antagonist like AC927 and CM156 [135,
149]. Even though several sigma receptors antagonists have been synthesized, a primary concern
with these compounds is that they are not solely sigma selective [150]. Most of these compounds
also bind to dopamine transporters, opioid receptors, or NMDA receptors.
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AZ66, 3-(4-(4-cyclohexylpiperazine-1-yl)pentyl)-6-fluorobenzo[d]thiazole-2(3H)-one, is
a synthetic piperazine derivative identified as a promising lead, based on its toxicological and
pharmacological data. Radioligand binding studies have shown that AZ66 has high nanomolar
affinity for both subtypes of sigma receptors. In addition, AZ66 exhibited an appreciably longer
half-life in vitro compared to CM156. AZ66 significantly attenuated the convulsions in mice
treated with toxic dose of cocaine, demonstrating its anticocaine activity [134].
3.2. Experimental
3.2.1. Chemicals and reagents
AZ66 (>99% purity, as determined using HPLC) provided by the Department of
Medicinal Chemistry, The University of Mississippi (Oxford, MS, USA). The internal standard
(IS), aripiprazole (99% purity), was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Acetic acid was purchased from Mallinckrodt Baker Inc. (Phillipsburg, NJ, USA). Methanol,
acetonitrile and water were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Ammonium
acetate was purchased from Sigma-Aldrich (St. Louis, MO, USA). Rat plasma was obtained
from Innovative Research (Peary Court Novi, MI, USA). All the solvents used were HPLC
grade.
3.2.2. Preparation of calibration standards and quality control (QC) samples
The stock solution of AZ66 (1.0 mg/mL) was prepared by dissolving accurately weighed
(Mettler Toledo, USA) amount (0.72 mg) of the compound in water (720 µL). A series (8) of
working standard solutions at concentrations ranging from 50 to 35,000 ng/mL were prepared by
transferring a measured quantity of stock solution in to a 1.5 mL eppendorf tube and diluting it
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with required amount of methanol. The stock solution was diluted with methanol to achieve good
sensitivity and response in mass spectrometry, as organic solvents give better sensitivity than
water. The IS stock solution (1.0 mg/mL) was prepared by dissolving 0.54 mg of compound in
540 µL of methanol transferred using an adjustable 1 mL eppendorf pipette. The working
standard solution (3 µg/mL) of IS was obtained by diluting 3 µL of the stock solution with 997
µL of methanol. All stock solutions were stored at -20 °C and brought to room temperature
before use. Calibration standards were freshly prepared by diluting the blank rat plasma (100 µL)
with 10 µL of working standard solutions of concentrations ranging from 10 to 35,000 ng/mL to
obtain final concentrations of 1, 10, 50, 100, 500, 1000, 2000 and 3500 ng/mL. Quality control
(QC) samples were prepared at three concentrations of 2, 400 and 3000 ng/mL. Blank rat plasma
(100 µL) was transferred to an eppendorf tube (1.5 mL) and to this appropriate amount of
working standard solutions of concentrations 20, 4000 and 30,000 ng/mL were transferred get
final concentrations of 2, 400 and 3000 ng/mL.
3.2.3. Sample Preparation
A liquid liquid extraction method was applied for the extraction of AZ66 from rat
plasma. Rat plasma samples (100 µL) were spiked with 10 μL measured using a pipette of the IS
(3 µg/mL) and vortexed for 30 s. The samples were extracted with 800 µL of chloroform by
vortex-mixing for 10 min and the resultant mixture was centrifuged (Accuspin 17R, Fisher
Scientific, USA) at 10,000 x g for 10 min at 4 °C. The organic phase was then transferred using a
1 mL pipette in to a 1.5 mL eppendorf tube and dried in a vacuum oven at 25 °C. The residue
was dissolved in 100 µL of methanol and vortex-mixed for 1 min and a 10 µL aliquot of sample
was injected into the UPLC/MS/MS for analysis using an autosampler (Waters Corp., Milford,
MA, USA).
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3.2.4. Liquid chromatographic and mass spectrometric conditions
The Acquity UPLC (Waters Corp., Milford, MA, USA) system consisted of a binary
solvent manager, vacuum degasser, temperature controlled column compartment and an autosampler. Chromatographic separation was achieved on an ACQUITY BEH RP C18 column (2.1
X 150 mm) at 25 °C. The mobile phase consisted of 10 mM ammonium acetate containing 0.1%
acetic acid and methanol (30:70, v/v) and pumped at a flow rate of 0.3 mL/min. The sample
injection volume was 10 µL. The total run time was 3.3 min. A Micromass Quattro microTM
system equipped with electrospray ionization source (ESI) was used for the mass spectrometric
detection. The ESI was operated in the positive ionization mode. The acquisitions were
performed using multiple reaction monitoring (MRM). The mass transitions chosen for
quantitation were m/z 405 → m/z 181 for AZ66 and m/z 448 → m/z 285 for the IS. Fig.3.1
shows the structures of AZ66 and IS. The optimized mass spectrophotometer parameters were as
follows: capillary voltage of 4.88 kV; cone voltage of 44 V; extractor voltage of 3 V; RF lens
voltage of 0.5 V; source temperature of 100 °C and desolvation temperature of 250 °C. The
desolvation and cone gas flows were set at 500 and 60 L/h, respectively. Argon was used as
collision gas at 3.5 × 10−3 Pirani. Collision energies were set at 30 and 21 eV for AZ66 and the
IS, respectively.

AZ66

Aripiprazole
66

Fig.3.1. Structures of AZ66 and Aripiprazole (IS)
3.2.5. Method validation
Method validation was performed according to the United States Food and Drug
Administration Bioanalytical Method Validation Guidance. The assay was validated for linearity,
lower limit of quantification, limit of detection, precision, accuracy, selectivity, recovery, matrix
effect and stability [151].
3.2.5.1. Selectivity and sensitivity
The selectivity of the assay was determined by comparing the chromatograms of blank
rat plasma from six different batches with corresponding plasma samples spiked with AZ66 and
the IS. Lower limit of quantification was defined as the lowest concentration that resulted in a
signal to noise (S/N) ratio of 10. The acceptable criteria for LLOQ were relative standard
deviation and relative error less than ±20%. The LLOQ was evaluated by analyzing samples in
six replicates on three consecutive days. The limit of detection was defined as the concentration
of analyte that yielded S/N ratio of 3.
3.2.5.2. Linearity
Calibration standards were prepared by spiking blank rat plasma with standard working
solutions of AZ66 to obtain concentrations of 1, 10, 50, 100, 500, 1000, 2000 and 3500 ng/mL.
An aliquot of 10 µL of IS was also added to get a concentration of 3 µg/mL. The calibration
curve was constructed by plotting the peak area ratios of analyte to the IS versus analyte
concentrations. The linearity of the calibration curve was evaluated by linear regression analysis.
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3.2.5.3. Recovery and matrix effect
The extraction recovery of AZ66 from rat plasma was determined at three QC
concentrations (2, 400 and 3000 ng/mL). The extraction recovery was calculated by comparing
the peak area ratios of blank plasma samples spiked with analyte and IS before extracting the
plasma, with peak area ratios of blank plasma samples to which analyte and IS were added after
the extracting the blank plasma. The matrix effect was determined at three QC levels (2, 400 and
3000 ng/mL) by comparing the analyte/IS peak area ratios of extracted plasma samples with
those of corresponding AZ66 standard solutions prepared in methanol.
3.2.5.4. Precision and accuracy
The precision and accuracy of the assay were assessed at three concentrations (2, 400 and
3000 ng/mL). To determine intra-day precision and accuracy, QC samples were analyzed in six
replicates at each concentration level. The inter-day precision and accuracy were determined by
analyzing QC samples on three consecutive days. The precision was expressed as relative
standard deviation and the accuracy as relative error. The intra-and inter-day precision and
accuracy should not be more than 15% of R.S.D and 15% of RE, respectively.
3.2.5.5. Stability
To determine the stability of AZ66 in rat plasma, QC samples (six replicates) at
concentrations of 10, 400 and 3000 ng/mL were exposed to various storage conditions including
short-term, long-term, freeze thaw and autosampler stability studies that may be encountered
during sample handling and analysis. Freeze-thaw stability was evaluated for three freeze/thaw
cycles at -20 °C. Short-term temperature stability was assessed at room temperature (37 °C) for
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12 h. For long-term stability, the samples were stored at -20 °C (Kenmore) for 30 days. Postoperative stability was also evaluated by analyzing the processed samples stored in the autosampler at 25 °C for 24 h. The stability of the stock solutions of analyte and IS was tested daily
for a period of 1 week. After the analysis the concentrations of the stored samples for all the
stability studies were compared with the freshly prepared standards.
3.2.6. Physicochemical characterization
The pKa of AZ66 was determined by potentiometric titrations [152] and ACD/Labs
(Algorithm Version: v12.1.0.3346, Toronto, ON, Canada). For the potentiometric titration
method, a 1 mM solution of AZ66 was prepared by dissolving 10.15 mg of compound in 25 mL
of water. To this solution, 25 µL of 0.01 M sodium hydroxide solution was added using a 200 µL
adjustable pipette (Fisher Scientific, NJ, USA) and the change in pH was recorded using a
Mettler Toledo S20 SevenEasy pH Meter (Fisher Scientific, NJ, USA). The procedure was
repeated until a constant pH was obtained. Thereafter, 25 µL of 0.01 M hydrochloric acid was
added continuously and the change in pH was recorded until a constant value is reached. The
titration curves were then constructed by plotting the recorded pH versus volume of base/acid
added. The intersection point of the curves was noted as the pKa of the compound.
As lipophilicity of the compound influences its transport across BBB, the octanol/water
and octanol/PBS pH 7.4 partition coefficients (Log P and Log D) of AZ66 were calculated. The
octanol/water (pH 6.4) and octanol/PBS (pH 7.4) partition coefficients (Log P and Log D7.4) of
AZ66 were determined using the stir flask method [153]. For the determination of Log P and
Log D, both phases (octanol, water/PBS) were saturated with one another for a period of 12 h
before beginning the experiment. A sample of AZ66 (0.54 mg) was accurately weighed and
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transferred to a clean glass vial (4 mL) and then to this 1 mL of the saturated aqueous phase
(with octanol) was added using a 1 mL Eppendorf pipette. To the above solution, 1 mL of
octanol (saturated with water) was added and stirred for 24 h on a VWR Dylastir magnetic stirrer
(Bridgeport, NJ, USA) using a magnetic bead. A 100 µL aliquot of the aqueous phase was
collected using a pipette, transferred in to a clean 1 mL plastic insert (Microsolv Technology
Corp., Eatontown, NJ, USA) that was already placed in a clean HPLC vial (Waters, MA, USA)
and analyzed by UPLC/MS/MS. Calibration curves prepared in phosphate buffer and water were
used for the determination of the compound concentration in aqueous phase. For the preparation
of calibration curve, 0.63 mg of compound was dissolved in 630 µL of acetonitrile to get a stock
solution of 1 mg/mL. From this solution, calibration standards were prepared by diluting with
buffer.
The solubility of AZ66 was determined in distilled water (pH 6.4) and in phosphate
buffer saline (pH 7.4) using the standard shake flask method. An excess amount (22 mg) of
AZ66 was added to 100 µL of the solvent in 2 mL glass vials. The vials were constantly agitated
(100 rpm) at room temperature (25 °C) for 24 h in reciprocating shaking water bath (Precision
Scientific, VA, USA) for uniform mixing. After 24 h, the samples were collected using a pipette
and centrifuged at 10,000 x g for 5 min. The supernatant was then analyzed using
UPLC/MS/MS.
3.2.7. In vitro metabolism
In vitro metabolism studies were performed on a series of seven sigma receptor ligands
(CM145, CM146, CM401, AZ68, AZ57, AZ66 and AZ77) using commercially available rat
liver microsomes. All the analogs were incubated with rat liver microsomes in Tris buffer (pH
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7.4). The standard incubation mixture contained 0.1 M MgCl2, 1 mM NADPH regenerating
system (NADP 1 mM, glucose-6-phosphate 5 mM, and glucose-6-phosphate dehydrogenase 1
Unit/mL), 1 mg of microsomal protein and 5 µM substrate. The final volume was adjusted to 1
mL with the appropriate amount of buffer. Incubations were performed at 37 °C and 100 rpm in
shaking water bath (Precision Scientific, VA, USA) for 30 min. Metabolic stability was assessed
quantitatively by measuring the disappearance of the substrate. After terminating the reaction
with ice-cold methanol at pre determined time points (0, 5, 10, 15, 30, 45, 60 and 90 min), the
mixture was vortexed and centrifuged. The supernatant was then analyzed by UPLC/MS/MS.
3.2.8. Determination of the human CYP enzymes responsible for AZ66 metabolism
For all most all the drugs, metabolism is the major route of elimination, and human liver
cytochrome P450 (CYP) enzymes play a key role in the oxidative biotransformation of many
drugs and xenobiotics. Any alterations of the activity of these enzymes lead to drug-drug
interactions. It is important to assess the contribution of metabolism by CYP to the overall
elimination process and to identify the specific P450 isoforms responsible for oxidative
reactions. Three families of P450 enzymes (CYP1, CYP2, and CYP3) are involved in the
metabolism of xenobiotics in humans, and CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9,
CYP2C19, CYP2D6, and CYP3A4/5 are responsible for the metabolism of the majority of drugs
[154]. Approaches used currently for the in vitro P450 reaction phenotyping typically involves,
antibody inhibition using potent and inhibitory antibodies, chemical inhibition by specific
chemical inhibitors, metabolism of drugs by recombinant P450 enzymes, and correlation
analysis.
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In our study the major CYP enzymes responsible for the formation of metabolites of
AZ66 were identified using selective chemical inhibitors for CYP isoforms. Compound AZ66
was incubated in Human Liver Microsomes (HLM) in the presence/absence of selective
chemical inhibitors of CYP1A1/CYP1A2 (5 µM α naphthoflavone) CYP2C8 (12 µM
quercetine), CYP2C9 (3 µM fluvoxamine) CYP2D6 (5 µM quinidine) and CYP3A4/A5 (3 µM
ketoconazole) [155-157]. Liver microsomes were preincubated with inhibitors for 15 min at
room temperature, followed by the addition of Tris buffer (pH 7.4), NADPH regenerating system
and substrate (10 µM). The final incubation volumes were 0.5 mL. All inhibitors were dissolved
in methanol and the concentration of the organic solvent in the incubation system was less than
1% (v/v). The nonspecific P450 inhibitor 1-benzylimidazole (BI) (1 mM) was used to assess the
P450-dependent metabolism of AZ66 [158, 159].
In addition to CYP mediated metabolism, several other enzymes, such as the flavincontaining monooxygenases (FMO), mediate the oxidative metabolism of xenobiotics and
endogenous substances. Mammalian flavin-containing monooxygenase is a hepatic microsomal
enzyme system that usually oxygenates drugs containing nitrogen or sulfur. The human FMO
functional gene family has 5 families each with a single member. Three of the human FMO
genes, FMO1, FMO2 and FMO3, are the most extensively studied among the five as they are the
primary isoforms that catalyze xenobiotic metabolism and these isoforms exhibit genetic
polymorphisms. FMO1 has the wide-range substrate acceptance, it can metabolize large
lipophilic compounds such as imipramine or orphenadrine, whereas, FMO3 selectively
metabolizes small amine-containing compounds such as trimethyl-amine [160]. To investigate
the potential role of FMO’s in the metabolism of AZ66, thermal inactivation that selectively
diminish FMO activity (FMO’s are thermally labile) [161] but not the P450 activity was done by
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preheating HLM at 45 °C for 5 min (without NADPH). HLM pre-incubated at 37°C for 5 min
was used as controls. These preheated or controls HLM were then incubated with the test
compound and NADPH, to determine the contribution of FMO. Effect of FMO activity on the
attenuation of AZ66 metabolism was further confirmed by the incubation of compound in HLM
with methimazole (100 µM), a selective FMO inhibitor [162]. All incubations were performed as
described previously.
3.2.9. Plasma protein binding
Unbound drug concentrations correlate better with the drug’s pharmacological response
and toxicity than the total drug concentration. Also, plasma protein binding can be a large factor
in the distribution of drugs in the body. Therefore, binding of drugs to plasma proteins is an
important factor in determining the pharmacokinetics and pharmacological effects. There are
numerous methods for the determination of in vitro protein binding, such as equilibrium dialysis,
ultrafiltration and ultracentrifugation [86]. Plasma protein binding of AZ66 was determined by
ultrafiltration method using Centrifree® devices [163]. The unbound concentration of AZ66 was
determined by spiking blank rat plasma with different concentrations of the test compound. Four
different concentrations were chosen including one below the Cmax, one at the Cmax, two above
the Cmax [164]. The plasma was then transferred to Centrifree® ultrafiltration device, incubated
for 15 min and then centrifuged at 1000 g for 30 min. To the resultant ultra filtrate, 10 µL of
internal standard (aripiprazole) was added and analyzed using UPLC/MS/MS. Ultrafiltration
method is not suitable for protein binding studies if the compound binds to the equipment to a
greater extent. The non specific binding should be less than 0.5 %. A control experiment was
done to estimate the nonspecific binding of the substrate to the equipment, which was
incorporated in the calculation of plasma protein binding [165].
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3.2.10. Pharmacokinetics studies
All the experimental procedures were approved and performed in accordance with the
guidelines of the Institutional Animal Care and Use Committee (IACUC) of the University of
Mississippi. Male Sprague Dawley rats (180-200 g) were obtained from Harlan Company
(Indianapolis, IN). The rats were purchased with pre-existing polyethylene cannula inserted into
their right jugular vein. The rats were quarantined for 72 h and fasted just 12 h before the
experiment. They were maintained in 12 h light and dark cycle for 72 h. They had access to
water and food during quarantine. During the experiment the rats were housed in metabolic
cages (Techniplast, USA) and allowed free movement and access to water.
The i.v formulation was prepared by dissolving 20.0 mg (accurately weighed) of AZ66 in
4 mL of saline. This solution was administered (0.5 mL) to rats (n=6) through the right jugular
vein cannula using a syringe at a dose of 5 mg/kg. For oral administration, AZ66 was accurately
weighed (40.2 mg) and dissolved in normal saline (4 mL). The solution was administered (1 mL)
to rats at a dose of 20 mg/kg using oral gavage. The formulations were prepared on the day of
dosing and filtered through 0.2 µ filter (Fisher Scientific, Pittsburgh, PA, USA) before
administration. Blood samples were collected from each rat’s indwelling cannula at intervals of
0, 2, 15, 30, 60, 120, 240, 360, 480 min, 12, 24, 30, 36 and 42 h after i.v injection, whereas for
the oral study the sampling was done at 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 18, 24, 30 36, 42 h after
dosing. To clear the heparinised saline from the cannula, a blood volume of 0.05 mL was
withdrawn and a clean syringe was then used to withdraw a 0.15 mL sample of blood. After each
blood sampling, the cannula was flushed with 0.2 mL of a heparin-saline (10 I.U./mL) solution.
Blood samples were transferred into heparinized micro centrifuge tubes and centrifuged
immediately at 10,000 × g for 10 min at 4 °C using an Accuspin Micro 17R centrifuge (Fisher
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Scientific, Pittsburgh, PA, USA). The plasma was separated from the blood cells, transferred to
clean eppendorf tube and was frozen at -20 °C (Kenmore) until analysis. The pharmacokinetic
parameters were calculated by non-compartmental analysis using WinNonlin 5.2 (Pharsight,
Mountain View, CA, USA).
Analysis of pharmacokinetic parameters
The pharmacokinetic parameters were calculated from the corresponding plasma
concentration-time curves using noncompartmental analysis (WinNonlin 4.0, Pharsight,
Mountain View, CA). The area under the plasma concentration–time curve from time 0 to
infinity (AUCinf) was calculated by the trapezoidal rule with extrapolation to time infinity. The
terminal t1/2 was calculated as 0.693/λz, where λz is the terminal phase rate constant. The plasma
clearance (CL) was calculated using the equation,

CL =

CL/F =

where Doseiv and AUCiv are the i.v dose and corresponding area under the plasma concentrationtime curve from time 0 to infinity, and Dose oral and AUC oral are oral dose and area under the
plasma concentration-time curve from time 0 to infinity, respectively. Volume of distribution
based on terminal phase (Vz) was calculated using

VZ =

VZ/F =

Absolute bioavailability (F) was calculated using the following equation
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AUC i.v and AUC oral are the areas under the plasma concentration-time curves of AZ66 after
i.v. and oral administration, respectively.
3.2.11. Urine sampling
Urine was collected in to BD vacutainer® containers at specified time intervals after both
oral (0-4, 4-8, 8-12 and 12-24 h) and i.v (0-2, 2-4, 4-8 h) administration of the compound. Blank
urine (urine before administering the test compound) that was collected from the graduated urine
collection tube of the metabolic cage was also transferred to a BD vacutainer®. The volume of
urine collected in graduated containers was noted during each time interval and kept frozen
(Kenmore) at -20 °C until analyzed. Urine samples were analyzed by UPLC/MS/MS for the
quantification of AZ66 in urine.
3.2.12. Multiple dose pharmacokinetics of AZ66 after oral administration
Rats were treated with AZ66 at dose of 30 mg/kg provided in an oral solution containing
0.5 mg of AZ66 per 0.5 mL of water (pH 6.4). The compound was administered at every half-life
(4 h) for 5 half-lives in order to attain steady state. Venous blood samples (0.15 mL) were
collected using a 1 mL syringe via the jugular vein cannula just before and 0.5, 1, 2 h after the
first, second, third and fourth doses. After the fifth dose (last), the samples were collected at 0.5,
1 and 2 h. The blood was transferred in to a heparinized micro centrifuge tube and centrifuged at
4 °C using an Accuspin Micro 17R centrifuge. The plasma (100 µL) was collected using a
pipette and transferred in to a clean eppendorf tube and stored at -20 °C until analyzed.
3.2.12.1. Tissue distribution and brain to plasma ratio studies
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At the end of the repeated dose study the animals were anesthetized, the body was cut
open and transcardially perfused with buffer until all the blood was removed from the organs.
After the perfusion, the tissues including brain, lung, liver, kidney and heart were excised and
washed with buffer. Tissues were weighed and quickly frozen at -20 °C. All tissues were
homogenized in 1 mL of water and the homogenates were processed and analyzed by the
developed and validated UPLC/MS/MS method described in section 3.2.3.
For the quantification of AZ66, all the tissues (lung, liver, kidney and heart) were thawed
to room temperature and homogenized using a tissue homogenizer, (Tekmark, OH, USA). To an
aliquot of 100 µL of the homogenate, 10 µL of IS was added and vortexed for 30 s. The mixture
was extracted with chloroform (800 µL) by vortexing for 5 min and then centrifuged at 10,000 x
g for 7 min. A fixed aliquot (725 µL) of the organic layer was collected after centrifugation and
subjected to evaporation in a vacuum oven (Precision Scientific, Winchester, VA, USA). The
residue was then reconstituted in 100 µL of water and an aliquot of 5 µL was injected using an
autosampler (Waters Corp., Milford, MA, USA) into the UPLCMS/MS for the quantification of
AZ66.
For the determination of brain to plasma ratio of AZ66, brains were thawed at room
temperature (25 °C) and transferred to a 20 mL glass vial. To this glass vial 3 mL of water was
added using a pipette and the brains were then homogenized using a tissue homogenizer,
(Tekmark, OH, USA). The homogenate was then transferred using a pipette in to a fresh
eppendorf tube (1.5 mL) and centrifuged at 10,000 x g for 10 min to remove the air that was
entrapped during homogenization. An aliquot (100 µL) of the homogenate was transferred using
a pipette into a clean eppendorf tube. To this homogenate 10 µL of IS (3 µg/mL) was added
using a pipette and vortexed for 30 s. The mixture was then extracted with chloroform (800 µL)
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by vortexing for 10 min and centrifuged using an Accuspin Micro 17R centrifuge at 10,000 x g
for 7 min. A fixed aliquot (725 µL) of the lower organic layer was collected after centrifugation
and subjected to evaporation in a vacuum oven (Precision Scientific, Winchester, VA, USA).
The residue was reconstituted in 100 µL of water and aliquot of 5 µL was injected into the
UPLC/MS/MS for the quantification of AZ66 in brain tissues. The plasma samples were
processed as described in the section 3.2.3 and analyzed using the developed and validated
UPLC/MS/MS for the quantification of AZ66 in plasma.
3.3. Results and Discussion
3.3.1. Method development
AZ66 being a basic compound exhibited a higher mass spectrometric response in ESI
positive mode compared to negative mode and [M+H]+ was found to be the most intense signal
with m/z at 406 [151]. Several fragment ions were observed in the product ion spectra, but the
most abundant product ions were at m/z 181 and 285 for AZ66 and the IS, respectively. The
mass spectrometric parameters such as collision energy, source temperature, capillary voltage,
gas flow were optimized to enhance the signal intensity. Fig.3.2. shows the product ion scans of
[M+H]+ of AZ66 and IS.
The chromatographic conditions were optimized through several trials to achieve good
chromatographic behavior and better ionization of AZ66 and IS. At first columns such as C18
and Atlantis dC18 were tried. These two columns resulted in good peak separation but the peaks
were broader with 0.4-0.5 min width. Tailing was also observed for the analyte and IS. To reduce
the tailing and get narrow peaks we tried columns like HILIC and ACQUITY UPLC BEH Shield
RP 18 and BEH Shield RP 18 column resulted in the best performance with a peak width of 0.278

0.25 min for both analyte and IS. Buffers, such as ammonium acetate, formic acid and acetic acid
were used alone or in combination at various concentrations for better peak shapes and higher
ionization. As the compound is basic in nature, acidic modifiers (such as acetic acid) ionize the
compound very well and result in much better sensitivity than the basic modifiers such as
ammonium hydroxide so we selected acidic modifiers for the assay [151]. Acetic acid resulted in
good sensitivity however the peak was not sharp. To improve the peak shape we added
ammonium acetate. Ultimately, a 0.1% acetic acid solution with 10 mM ammonium acetate in
water and methanol (30:70, v/v) was chosen as the mobile phase. This mobile phase resulted in
good peak shapes and high sensitivity (LOD 0.5 ng/mL). The retention times of AZ66 and the IS
were 1.3 and 1.0 min, respectively, with a total run time of 3.3 min.
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Fig. 3.2. Protonated molecular ion mass spectra of AZ66 (A), aripiprazole (B)
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3.3.2. Method validation
3.3.2.1. Selectivity and sensitivity
Fig. 3.3. represents typical chromatograms obtained from the analysis of blank plasma,
blank plasma spiked with AZ66 and the IS, and rat plasma sample obtained 1 h after the oral
administration of AZ66. No obvious interferences were observed at the retention times of AZ66
and the IS. The LLOQ for AZ66 in plasma was 1 ng/mL with precision (R.S.D.) below 20% (1.7
%) and accuracy (RE) within ±20% (2.5 %). A corresponding chromatogram is shown in Fig .
2b. The limit of detection (LOD) was defined at a signal-to-noise (S/N) ratio of 3:1 [151] and it
was found to be 0.5 ng/mL. This method was found to be sensitive enough to investigate the
pharmacokinetic behavior of AZ66 in rats.
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Fig. 3.3. Representative MRM chromatograms for AZ66 and Aripiprazole (IS) in rat plasma: (A)
Total ion chromatogram of AZ66 and IS; (B) blank plasma sample; (C) blank plasma sample
spiked with AZ66 at 400 ng/mL and aripiprazole (IS) at 3 µg/mL; (D) rat plasma sample
obtained at 1.0 h after oral administration at a dose of 20 mg/kg.
3.3.2.2. Linearity of calibration curve
Fig. 3.4 shows the calibration curve of AZ66 in rat plasma. The calibration curves for
AZ66 were linear over the concentration range of 1 to 3500 ng/mL (r2 > 0.99). The
representative regression equation for the calibration curve was:
y = 0.0511x + 0.1682
Where y represents the peak area ratios of AZ66 to the IS and x represents plasma concentrations

Analyte Peak area/IS
Peak area

of analyte. The R.S.D. of the slope was 0.00018 and the R.S.D. of the intercept was 0.0031.
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Fig. 3.4. AZ66 calibration curve in rat plasma
3.3.2.3. Precision and accuracy of the assay
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The results of the intra- and inter-day precision and accuracy are presented in Table 3.1.
The intra-day precision for the three QC levels of AZ66 was 2.0%, 0.1% and 0.1% and the interday precision were 3.0%, 0.4% and 0.1%. The intra- and inter-day accuracy of the method
ranged from 0.3% to 6.3%. The data indicates that the precision and accuracy were within the
acceptable limits specified by US-FDA where the precision (R.S.D.) determined should not
exceed 15% and accuracy (RE) should be within±15% of the actual value. These results suggest
that the present method is consistent and reproducible for the quantitation of AZ66 in rat plasma.
Spiked
concentration
(ng/mL)

2
400
3000

Intra-day precision and accuracy
(n=6)
Measured
R.S.D.
concentration
(%)
(mean ±SD, ng/mL)
2.0 ± 0.02
2.0
401.4 ± 0.5
0.1
3008.1 ± 3.7
0.1

R.E
(%)
1.7
0.4
0.3

Inter-day precision and accuracy
(n=6)
Measured
concentration
(mean ±SD, ng/mL)
2.1 ± 0.03
402.8 ± 1.6
3009.7 ± 4.3

R.S.D.
(%)
3.0
0.4
0.1

R.E
(%)
6.3
0.7
0.3

Table 3.1. Summary of the accuracy and precision of AZ66 in rat plasma
3.3.2.4. Recovery and matrix effect
According to US-FDA guidelines the recovery of analyte and IS needs to be invariable
and reproducible and need not be 100 %. The extraction recoveries of AZ66 were 97.8 ± 3.3%,
101.12 ± 1.5% and 99.4 ± 4.7% for QC samples at the concentrations of 2, 400 and 3000 ng/mL,
respectively. These results suggested that the recovery of AZ66 was precise and reproducible at
all the three concentrations. The extraction recovery of the IS was consistent and found to be
69.4 ± 3.5%.
The matrix effect of AZ66 was evaluated by analyzing QC samples at three concentration
levels of 2, 400 and 3000 ng/mL. The mean matrix effect values ranged from 96.5 to 101.4%.
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The matrix effect of the IS was 95.4%. This indicated that the ion suppression from plasma
matrix for AZ66 and IS was negligible.

Solvent

%Recovery of
AZ66 in QC’s

Acetonitrile

45

Methanol

68

Chloroform

98

Ethyl acetate

63

Methyl tert-butyl ether
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Table 3.2. Recovery of AZ66 in various solvents

Conc (ng/mL)

Recovery
(%) ± SD

2

97.8 ± 3.3

400

101.1 ± 1.5

3000

99.4 ± 4.7

Table 3.3. Recovery of AZ66 from spiked rat plasma
3.3.2.5. Stability
To investigate the stability of AZ66 in rat plasma, QC samples at three concentrations of
10, 400 and 3000 ng/mL, were stored under various conditions which may be encountered during
routine sample handling, processing and analysis. Table 3.4 summarizes the results of the freeze–
thaw, short-term, long-term, and postoperative stabilities of AZ66 in rat plasma. The stability of
AZ66 was evaluated under different conditions at three concentrations (10, 400 and 3000
ng/mL).
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Storage condition
Three freeze thaw cycles

Concentration (ng/mL)
Spiked
Measured
10
10.2 ± 0.7
400
396.1 ±12.7
3000
2990.6 ± 42.9

R.S.D. (%)

RE (%)

6.9
3.2
1.4

-3.1
-0.6
0.2

Long term for 30 days (-20 °C)

10
400
3000

10.2 ± 0.4
402.4 ± 7.1
3028.2 ± 55.0

3.9
1.8
1.8

0.3
-0.4
-0.6

Short term for 12h (25 °C)

10
400
3000

10.2 ± 0.2
401.4 ± 3.5
3015.4 ± 30.6

2.4
0.9
0.9

1.3
-0.5
1.0

Auto sampler for 24h (25 °C)

10
400
3000

10.1 ± 0.2
403.2 ±18.6
3222.1 ± 79.4

2.0
4.6
2.5

1.7
0.8
4.1

Table 3.4. Results of the stability studies of AZ66 at different storage conditions
The results indicated that AZ66 was found to be stable after three freeze/thaw cycles, at
room temperature for 12 h, at -20 °C for 30 days. The compound was also stable in reconstituted
samples stored in the auto-sampler at 25 °C for 24 h. The stock solutions of AZ66 and the IS
were stable for at least 12 h at room temperature and for one week at -20 °C. No loss of
compound was observed at all the storage condition examined, suggesting that the plasma
samples can be stored at -20 °C for a period of 30 days after the pharmacokinetic study.
3.3.3. Determination of pKa, lipophilicity and solubility
Physicochemical properties commonly affect the transport of drugs passively across the
membranes [166]. Various physicochemical properties including pka, lipophilicity and solubility
were determined for AZ66 using different in vitro methods described earlier. The pKa was found
to be 8.4 indicating that the compound is basic in nature. The estimated limits for pKa of CNS
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drugs for greater penetration are between 4 and 10. The lipophilicity of a compound is one of the
main components that affect BBB permeability. The Log P and Log D of the compound AZ66
were 0.59 and 2.4, respectively. The optimal Log D 7.4 for CNS drugs is around 2. The acid
ionization constant and lipophilicity values indicate that AZ66 can cross the blood brain barrier
to an appreciable extent [167]. The solubility of AZ66 in water and phosphate buffer saline (pH
7.4) was found to be 50 and 23 mg/mL, respectively.
3.3.4. In vitro metabolism
The half-lives of the compounds ranged from 15 min to 115 min. The in vitro half-lives
and respective intrinsic clearance values for the series of sigma ligands along with their chemical
structures are presented in table 3.5. The rank order of metabolic stability was found to be AZ66
> AZ57 > AZ68 > CM145 > AZ77 > CM156. The microsomal metabolism of two analogs
CM156, AZ77 was rapid and extensive with > 90% loss of the parent compound in 30 min and
the half-life (t1/2) was less than 15 min. AZ68, AZ57, CM145 exhibited moderate stability with
30-40% parent compound remaining after 60 min. The results demonstrated that the metabolic
stability greatly increased with the insertion of stable groups like methyl and fluorine in the
weakest spots. Also it was observed that replacing thiazole-2(3H)-thione in CM156 with
thiazole-2(3H)-one in AZ66 resulted in higher metabolic stability in in vitro. The in vitro halflife of AZ66 was 115 min with only 20% of the parent compound disappearing after a 60 min
incubation period.
The C-N linkage and the thiazole-2(3H)-thione moiety were identified as the most labile
sites (i.e., soft spots) to metabolism from the metabolite identification of CM156 in urine and
liver microsomes. The next generation of sigma compounds (AZ66, AZ57, AZ68, CM145, and

86

AZ77) were then designed with an aim to improve the metabolic stability of the compounds by
blocking these soft spots. All the analog compounds possessed the replacement of the thiazole2(3H)-thione with thiazole-2(3H)-one except for AZ77. In addition, these compounds were made
to modify the link between the cyclohexylpiperazine and benzothiazole ring. They also had a
fluorine group attached to C-6 on the aromatic ring. Fluorine, because of its inductive effect,
would be expected to affect the electrophilic oxidation of the substituted carbon by oxidative
enzymes like cytochrome P450. These (AZ66, AZ57 and AZ68) compounds showed enhanced
metabolic stability than all the other compounds (CM156, CM145, AZ77). However, the
insertion of a fluorine group without replacing the sulfur atom with oxygen as in compound
AZ77, failed to increase the metabolic stability in rat liver microsomes. This might indicate that
sulfur oxidation is the major metabolic pathway. This was also further supported by the greater
metabolic stability of the other analogs (AZ57) with modifications in the butyl chain and
thiazole-2(3H)-thione ring without the fluorine group.
A dramatic increase in microsomal metabolic stability was observed with AZ66, 3-(4-(4cyclohexylpiperazin-1-yl)pentyl)-6-fluorobenzo[d]thiazol-2(3H)-one. This compound showed a
30-fold longer stability than our 1st generation compound, CM156, in rat liver microsomes.
AZ68 and AZ57 also exhibited a 20-fold increase in metabolic stability. Compounds that
contained sulfur (CM156, AZ77) showed poor metabolic stability, which might be due to the
high susceptibility of sulfur atom to metabolism. Thus, AZ66 was identified as the promising
compound that demonstrated high metabolic stability and affinity to sigma receptors and was
selected for pharmacokinetic studies.
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Half-life
(min)

Intrinsic clearance
(ml/min/kg)

CM156

4.6

270

CM145

31.0

40.2

AZ77

14.8

84.3

AZ57

68.0

18.3

AZ68

47.1

26.5

AZ66

115.6

10.8

Substrate

Structure

Table 3.5. Structures, in vitro half-life and Intrinsic clearance values of sigma receptor ligands.
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3.3.5. CYP reaction phenotyping
Metabolism of xenobiotics can be affected by many parameters, including genetic
polymorphisms, high inter-individual variability, and gender differences. Because variable
expressions of individual isozymes can affect the metabolic fate of a drug candidate, it is
important to determine which P450 enzymes contribute to the metabolic process. Chemical
inhibitors and thermal inactivation were used to estimate the relative contribution of P450 and
FMO isoforms involved in AZ66 metabolism in human liver microsomes. The findings are
described below.
AZ66 metabolism was markedly decreased in HLM in the presence of a combination of
CYP-specific inhibitors and a non-specific CYP inhibitor, confirming that AZ66 is most likely
metabolized by diverse CYP isoforms. The individual isozymes responsible for the
biotransformation of AZ66 were determined to be CYP3A4 (an important enzyme in xenobiotic
metabolism) with a small contribution from CYP2C8 and CYP2D6. The overall metabolism of
AZ66 was significantly inhibited by 3 µM ketoconazole (CYP3A4; 30.1%). Some inhibition was
observed with 5 µM quercetin (CYP2C8; 12.7%) and 3 µM Quinidine (CYP2D6; 4.5%). αnaphthoflavone has shown negligible effect at 5 µM but inhibited up to 30% at a concentration
of 100 µM. Nonspecific P450 inhibitor BI, potently inhibited parent compound consumption to a
greater extent (40%). This further confirmed the substantial contribution of P450-dependent
enzymes to the metabolism of AZ66. A role of flavin-containing mono-oxygenases was
anticipated based on their known ability to catalyze N-oxidation reactions. The potential
contribution of FMO to the metabolism of AZ66 was investigated using chemical inhibitor
Methimazole and the heat lability of FMO’s in human liver microsomes. It was found that the
metabolism of AZ66 was not markedly (4%) inhibited by FMO’s. This suggested that FMO’s
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does not contribute appreciably to metabolism of AZ66 in human liver microsomes. Table 3.6
represents the percent inhibition of metabolism of AZ66 in the presence of various inhibitors for
CYP450 and FMO. Fig.3.5 shows the effect of chemical inhibitors on the metabolism of AZ66
(10 µM).
Overall, CYP3A4, CYP2C8 and CYP1A1 (100 µM) enzymes were considered as major
enzymes catalyzing AZ66 metabolism with minor contributions from CYP2D6. From the
phenotyping results, we may conclude that, even if co-administered drugs inhibit one of the
identified drug-metabolizing enzymes, the pharmacokinetics of AZ66 is unlikely to be noticeably
affected due to probable metabolic compensatory mechanisms produced by other CYP isoforms.

Enzyme

Inhibitor

% Inhibition

% Remaining

-------

Control

-----

51

CYP1A1

α-naphthofalvone

2

53

CYP2D6

Quinidine

5

56

CYP2C8

Quercetine

13

64

CYP2C9

Fluvoxamine

2

53

CYP3A4

Ketoconazole

30

80

CYP (Non
specific)
FMO (Non
specific)

1-benzylimidazole

37

88

Methimazole

4

60

FMO Inhibition

Heat inactivation

5

56

Table 3.6. Percent inhibition of metabolism of AZ66 in the presence of various selective and
non-selective inhibitors for CYP450 and FMO.
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Fig.3.5. Effect of chemical inhibitors on the metabolism of AZ66 (10 µM)
3.3.6. In vivo pharmacokinetics
Figures 3.6 and 3.8 represent the mean plasma concentration-time profiles of AZ66 after
i.v and oral routes of administration. The pharmacokinetic parameters are summarized in Tables
3.7 (intravenous) and 3.8 (oral). After an i.v administration, Vd was extensive (12.6 L/kg)
indicating a high tissue distribution. The plasma clearance and the half-lives were 4.1 L/h/kg and
4.2 h, respectively. After oral administration, the plasma kinetics shows that AZ66 was absorbed
rapidly and had a Tmax of 2.0 h. The Cmax was found to be 0.3 µg/mL that was maintained at
the same level for 4 h. The longer-lasting terminal phase (3–14 h) might have contributed to the
high MRT (8.8 h). The compound exhibited moderate absolute bioavailability (58.2%) indicating
a low first-pass metabolism in rats. To confirm the half-life observed after oral administration the
study was again repeated in 6 animals. The half-life correlated with the previous study. The new
parameters and the plasma profile were shown in table 3.9 and figure 3.10, respectively. The
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difference between the half lives after i.v (3.9 h) and oral (8.7 h) administration was very high.
The i.v study was conducted for 8 h and it is only twice the t1/2 observed after i.v administration.
To get a correct estimate of the half-life the time period of the study needs to be at least 4-5 times
of the observed t1/2. In the present case the study period was 8 h and it might have resulted in
wrong estimation of the t1/2 as the terminal elimination was missing in the study. To estimate the
correct t1/2 the i.v study was again conducted for 42 h which would be equal to 5 times of the
half-life observed after oral administration. The new t1/2 observed after the 42 h study was 7.9 h
which is very close to the oral t1/2. The new Cmax and the CL were found to be 1.21 µg/mL and
2.63 L/h/kg. The new PK parameters and the plasma profile after i.v administration were
represented in table 3.10 and figure 3.12, respectively. To further confirm the t1/2 observed after
oral administration, oral PK study was also repeated again in 2 rats and the t1/2 (8.25 h) was
found to be similar to two previous studies. The new PK parameters and the plasma profile after

Plasma Conc (ng/mL)

oral administration were represented in table 3.11 and figure 3.13, respectively.
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Fig.3.6 Pharmacokinetic profile of AZ66 after intravenous administration to rats at 5 mg/kg
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Fig. 3.7. Log plasma concentration time profile after single intravenous dosing of AZ66

Parameter

Mean ± SD

t1/2 (h)
Cmax (µg/mL)
AUC0→∞ (µg h/mL)
Vd (L/kg)
CL (L/h/ kg)
MRT (h)

3.9 ± 0.4
1.1 ± 0.1
63.2 ± 6.1
12.6 ± 0.6
4.1 ± 0.2
4.1 ± 3.3

Table 3.7 Pharmacokinetic parameters of AZ66 in rats following a single i.v dose of 5 mg/kg
(Mean±SD, n = 5).
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Fig. 3.8. Pharmacokinetic profile of AZ 66 after Oral administration to rats at 20 mg/kg (n=6)
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Fig. 3.9. Log plasma concentration time profile after oral dosing of AZ66

Parameter

Mean ± SD

t1/2 (h)

8.8 ± 0.3

Cmax (µg/mL)

0.3 ± 0.02

AUC0→∞ (µg h/mL)

158.2 ± 2.8

Vd (L/kg)

78.1 ± 0.9

CL/F (L/h/ kg)

6.15 ± 0.1

MRT (h)

8.8 ± 0.2

Table 3.8 Pharmacokinetic parameters of AZ66 in rats following a single intravenous dose of 5
mg/kg (Mean±SD, n = 5).
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Fig. 3.10. Pharmacokinetic profile of AZ 66 after Oral administration to rats at 20 mg/kg (n=6)
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Fig. 3.11. Log plasma concentration time profile after oral dosing of AZ66

Parameter

Mean ± SD

t1/2 (h)

8.9 ± 0.6

Cmax (µg/mL)

0.3 ± 0.04

AUC0→∞ (µg h/mL)

148.2 ± 2.8

Vd (L/kg)

74.1 ± 0.2

CL/F (L/h/ kg)

6.1 ± 0.4

MRT (h)

9.1 ± 0.3

Table 3.9. Pharmacokinetic parameters of AZ66 in rats following a single oral dose of 20 mg/kg

Conc ng/mL

(Mean±SD, n=6).
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Fig. 3.12. Plasma concentration vs time profile after i.v administration of AZ66 at a dose of 5
mg/kg
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Parameter

Mean ± SD

t1/2 (h)
Cmax (µg/mL)
AUC0→∞ (µg h/mL)
Vd (L/kg)
CL (L/h/ kg)

7.9 ± 0.3
1.2 ± 0.2
73.2 ± 8.1
30.1 ± 3.6
2.6 ± 0.4

Table 3.10. PK parameters of AZ66 in rats following i.v dose of 5 mg/kg (Mean±SD, n=6).
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Fig. 3.13. PK profile of AZ 66 after oral administration to rats at 20 mg/kg (n=2)

Parameter

Mean ± SD

t1/2 (h)

8.2 ± 0.3

Cmax (µg/mL)

0.3 ± 0.01

AUC0→∞ (µg h/mL)
Vd/F (L/kg)

178.2 ± 7.8
64.1 ± 1.6

CL/F (L/h/ kg)

6.4 ± 0.1

MRT (h)

9.9 ± 0.1

Table 3.11. PK parameters of AZ66 in rats after single oral dose of 20 mg/kg (Mean±SD, n=2).
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3.3.7. Plasma protein binding
Protein binding of AZ66 was determined by the ultrafiltration method using Centrifree®
devices [163]. Four different physiologically relevant concentrations of the test compound were
used to assess the extent of protein binding. AZ66 bound moderately to rat plasma proteins with
71.3% binding. Protein binding did not increase with increase in concentration of the compound
in the plasma and thus was independent of concentration. Table 3.12 represents the protein
binding of AZ66 in rat plasma. The nonspecific binding of the compound to the components of
Ultracentrifree® was less than 0.2%.
Conc of AZ66
(ng/mL)
700
1000
2000
3000

% Binding
72.1
69.5
71.6
72.0

Table 3.12. Plasma protein binding of AZ66 at different concentrations
3.3.8. Multiple dose pharmacokinetic studies
Fig.3.14. shows the log plasma concentration time profile after multiple oral dosing of
AZ66. Peak plasma levels achieved after the last dose was found to be 0.49 µg/mL. Trough
levels just before the next dose were consistently in the range of 0.13 to 0.3 µg/mL. The mean
plasma and tissue levels of AZ66 after administration of 30 mg/kg per every 4 h are summarized
in Fig.3.14 and Table 3.13. C1,min, the trough concentration after first dosing was 0.13 µg/mL.
Peak concentration in plasma after the first and last dose (Cmax) was found to be 0.25 and 0.49
µg/mL, respectively. The time to attain Cmax (Tmax) was 2 h and it did not change during
repeated doses. The accumulation factor (R) was 2.37, calculated as the ratio of Css,min to C1,min.
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The area under the plasma concentration-time curve of a dosing interval after the first and last
dose (AUC0–4), determined by trapezoidal summation were found to be 37.1 and 100.5
µg*min/mL, respectively. After 5 half-lives, AZ66 was present in brain and peripheral tissues in
measurable amounts. The concentration was highest in lungs (13.3 µg/gm) compared to all other
tissues. The mean brain/plasma ratio for AZ66 was 7.54±0.46. The results indicate that AZ66
readily absorbed and distributed in brain and other tissues and accumulated after the multiple
dosing.
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Fig.3.14. Log plasma concentration time profile after multiple oral dosing of AZ66.
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Fig.3.15. Mean plasma and tissue levels after administration 30 mg/kg per every 4 h.
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Conc. (µg/gm) in
Tissues
Tissues after 5 doses
Plasma

0.51

Brain

3.87

Heart

1.86

Liver

7.68

Kidney

9.68

Lung

13.33

Table 3.13. The mean plasma and tissue levels after administration 30 mg/kg per every 4 h.
3.3.8.1. Brain to plasma ratio
The extent of CNS penetration of the compound AZ66 was determined using Brain to
Plasma ratio study. The compound was administered orally at a dose of 30 mg/kg for five halflives to a attain steady state. At the end of the study the brains were harvested and analyzed to
determine the B/P ratio. The results showed that AZ66 crossed the BBB and penetrated in to the
brain tissue to a greater extent. The B/P ratio of the compound AZ66 was found to be 7.54 ±
0.46. Table 3.14. shows the B/P ratio of AZ66 in rats after repeated oral dosing. The brain
concentration was 7.5 times greater than the plasma. The high volume of distribution observed
during the single dose studies further confirms its high tissue distribution.

Dose
(mg/kg)

30

Concentration

No of
Doses

5

B/P ratio
Brain (µg/gm)

Plasma (µg/mL)

3.87

0.51

99

7.54 ± 0.46

Table 3.14. Brain to plasma ratio of AZ66 in rats after repeated oral dosing
3.4. Conclusions
Though AZ66 is a structural analogue of CM156, its pharmacokinetic behavior was
relatively different. CM156 has a plasma t1/2 of 1 h after i.v. administration where as for AZ66 it
is 7.9 h which is very much greater than that of CM156. More rapid clearance from plasma and
low Vd of CM156 (6.2 mL/min/kg, 9.6 L/Kg) compared to AZ66 (2.6 mL/min/kg, 30.6 L/Kg)
might have contributed to this difference. The modification in chemical structure resulted in
altered physicochemical parameters i.e. the replacement of sulfur atom in CM156 with oxygen in
AZ66 decreased the pKa and log D. This may be explained as one of the possible reason for the
higher metabolic stability of AZ66 compared to CM156. The low pKa reduced the lipophilicity
of AZ66, as more amount of the compound remains in the neutral form and thus it exhibited
comparatively less protein binding and high stability. A bioanalytical method was developed and
validated for the determination of AZ66 in rat plasma and has been applied for pharmacokinetic
studies in rats. The preclinical pharmacokinetic studies demonstrated that AZ66 has excellent
oral bioavailability, a long half-life and low clearance. The results indicate that AZ66 readily
absorbed and distributed in to brain and other tissues and accumulated after the multiple dosing.
Together, all these studies show that first AZ66 has good efficacy and ADME properties,
justifying further development of this compound towards clinical candidate status.
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